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Abbreviations: CI, confidence interval; GWAS, genome-wide association study; LD, linkage 
disequilibrium; OR, odds ratio; kb, kilobase; Mb, megabase; PCA, principal components 
analysis; DHS, DNase1 hypersensitivity site. 
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Abstract 
 
We conducted a meta-analysis of three endometrial cancer GWAS and two replication 
phases totaling 7,737 endometrial cancer cases and 37,144 controls of European ancestry. 
Genome-wide imputation and meta-analysis identified five novel risk loci of genome-wide 
significance at likely regulatory regions on chromosomes 13q22.1 (rs11841589, near KLF5), 
6q22.31 (rs13328298, in LOC643623 and near HEY2 and NCOA7), 8q24.21 (rs4733613, 
telomeric to MYC), 15q15.1 (rs937213, in EIF2AK4, near BMF) and 14q32.33 (rs2498796, in 
AKT1 near SIVA1). A second independent 8q24.21 signal (rs17232730) was found. 
Functional studies of the 13q22.1 locus showed that rs9600103 (pairwise r2=0.98 with 
rs11841589) is located in a region of active chromatin that interacts with the KLF5 promoter 
region. The rs9600103-T endometrial cancer protective allele suppressed gene expression 
in vitro suggesting that regulation of KLF5 expression, a gene linked to uterine development, 
is implicated in tumorigenesis. These findings provide enhanced insight into the genetic and 
biological basis of endometrial cancer. 
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Endometrial cancer is the fourth most common cancer in women in the United States1 and 
Europe2, and the most common cancer of the female reproductive system. The familial 
relative risk is ~23,4, but highly penetrant germline mutations in mismatch repair genes5, and 
DNA polymerases6,7 account for only a small proportion of the familial aggregation. Our 
previous GWAS and subsequent fine-mapping identified the only two reported genome-wide 
significant endometrial cancer risk loci, tagged by rs11263763 in HNF1B intron 18 and 
rs727479 in CYP19A1 intron 49.  
 
To identify additional endometrial cancer risk loci, we re-analysed data from our previous 
GWAS (ANECS, SEARCH datasets10) and conducted a meta-analysis with two further 
studies (Supplementary Figure 1). The first was an independent GWAS; the National Study 
of Endometrial Cancer (NSECG), including 925 endometrial cancer cases genotyped using 
the Illumina 660W array, 1,286 cancer-free controls from the CORGI/SP1 GWAS11,12 and 
2,674 controls from the 1958 Birth Cohort13. The second study comprised 4,330 endometrial 
cancer cases and 26,849 controls from Europe, the United States and Australia, genotyped 
using a custom array designed by the Collaborative Oncological Gene-environment Study 
(COGS) initiative14-17 (Supplementary Table 1, Supplementary Note).  
 
We first performed genome-wide imputation using 1000 Genomes Project data, allowing us 
to assess up to 8.6 million variants with allele frequency 1% across the different studies. 
Per-allele odds ratios and P-values for all SNPs in the GWAS and iCOGS were obtained 
using a logistic regression model. There was little evidence of systematic overdispersion of 
the test statistic (λGC=1.002-1.038, Supplementary Figure 2). A fixed-effects meta-analysis 
was conducted for all 2.3 million typed and well-imputed SNPs (info score>0.90) in a total of 
6,542 endometrial cancer cases and 36,393 controls. The strongest associations were with 
SNPs in LD with previously identified endometrial cancer risk SNPs in HNF1B8,10,18 and 
CYP19A19,19 (Figure 1, Table 1). For fourteen 1.5Mb regions containing at least one novel 
SNP with Pmeta<10
−5, we performed regional imputation using an additional reference panel 
that comprised 196 high-coverage whole genome-sequenced UK individuals 
(Supplementary Table 2).  
 
Five novel regions containing at least one endometrial cancer risk SNP with Pmeta<10
−7 were 
identified and the most strongly associated SNP in each region was genotyped in an 
additional 1,195 NSECG endometrial cancer cases and 751 controls using competitive 
allele-specific PCR (KASPar, KBiosciences) and the Fluidigm BioMark System 
(Supplementary Table 3). Duplicate samples displayed concordance >98.5% between 
different genotyping platforms (Supplementary Table 4). All five SNPs were associated with 
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endometrial cancer at genome-wide significance (P<5×10−8, Table 1, Figure 2, Figure 3), 
and these associations remained highly significant when analysis was restricted to cases 
with endometrioid subtype only. Endometrioid-only analysis did not reveal any additional risk 
loci. eQTL analysis (Online Methods) in normal uterine tissue20, and endometrial cancer 
tumor and adjacent normal tissue21 did not yield any SNPs robustly associated with the 
expression of nearby genes at the endometrial cancer risk loci (Supplementary Table 5). 
However, for each risk locus, bioinformatic analysis including cell-type-specific expression 
and histone modification data identified correlated SNPs within 500kb in likely enhancers 
and multiple potential regulatory targets (Supplementary Table 6, Supplementary Figure 
3). The most compelling candidates for future functional analysis are described below. 
 
rs13328298 (OR=1.13, 95%CI:1.09–1.18, P=3.73×10−10) on 6q22.31 lies in the long non-
coding RNA LOC643623, 54kb upstream of HEY2 and 86kb upstream of NCOA7. HEY2 is a 
helix-loop-helix transcriptional repressor in the Notch pathway, which maintains stem cells, 
and dysregulation has been associated with different cancers22. NCOA7 modulates the 
activity of the estrogen receptor via direct binding23.  
 
The second locus (rs4733613, OR=0.84, 95%CI:0.80–0.89, P=3.09×10−9) is at 8q24.21. 
Stepwise conditional logistic regression identified another independent signal in this region, 
rs17232730 (pairwise r2=0.02, Pcond=1.29×10
−5, Table 2). Both endometrial cancer SNPs lie 
further from MYC (784-846kb telomeric) than most of the other cancer SNPs in the region, 
including those for cancers of the bladder24,25, breast15,26, colorectum12,27, ovary28 and 
prostate29,30. rs17232730 is in moderate LD with the ovarian cancer SNP rs10088218 
(r2=0.43), with both cancers sharing the same risk allele, but rs4733613 is not in LD (r2≤0.02) 
with any other cancer SNP in the region (Supplementary Figure 3). A role in tumorigenesis 
is implicated for several miRNAs in the region31. Of these, miR-1207-5p is reported to 
repress TERT, a locus also implicated in endometrial cancer risk32. 
 
The lead SNP at 15q15 (rs937213; OR=0.90, 95%CI:0.86–0.93, P=1.77×10−8) lies within an 
intron of EIF2AK4. EIF2AK4 encodes a kinase that phosphorylates EIF2α and 
downregulates protein synthesis during cellular stress33. Another nearby gene, BMF, 
encodes an apoptotic regulator moderately to highly expressed in glandular endometrial 
tissue34.  
 
At 14q42, the lead SNP rs2498796 (OR=0.89, 95%CI:0.85–0.93, P=3.55×10−8) lies in intron 
3 of oncogene AKT1, which is highly expressed in the endometrium34. Several SNPs in LD 
with rs2498796 are bioinformatically linked with regulation of AKT1 and four other nearby 
 7 
genes (SIVA1, ZBTB42, ADSSL1 and INF2; Supplementary Table 6, Supplementary 
Figure 3). AKT1 acts in the PI3K/AKT/MTOR intracellular signaling pathway, which affects 
cell survival and proliferation35 and is activated in endometrial tumors36, especially 
aggressive disease37-39. SIVA1 encodes an apoptosis regulatory protein that inhibits p53 
activity40,41 and enhances epithelial–mesenchymal transition to promote motility and 
invasiveness of epithelial cells42. INF2 expression is reported to act as a promigratory signal 
in gastric cancer cells treated with mycophenolic acid43.  
 
The final novel endometrial cancer SNP was rs11841589 (OR=1.15, 95%CI:1.11–1.21, 
P=4.83×10−11) on chromosome 13q22.1, 163kb and 445kb downstream from Kruppel-like 
factors KLF5 and KLF12, respectively. KLF5 is a transcription factor associated with cell 
cycle regulation, and it plays a role in uterine development, homoeostasis and 
tumorigenesis44-47. Elevated KLF5 levels are strongly correlated with activating KRAS 
mutations 48 and KLF5 is targeted for degradation by the tumor suppressor FBXW7. Both 
FBXW7 and KRAS are commonly mutated in endometrial cancer 49. rs11841589 was one of 
a group of five highly correlated SNPs (r20.98) surpassing genome-wide significance in a 
3kb LD block bounded by rs9600103 (P=8.70×10−11) and rs11841589 (Figure 4a). There 
was no residual association signal at this locus (Pcond >0.05) after conditioning for 
rs11841589. Bioinformatic analysis suggested that the causal variant at the intergenic 
13q22.1 locus may affect a regulatory element that modifies KLF5 expression 
(Supplementary Figure 3); rs9600103 overlaps a vertebrate conservation peak, and a 
DNaseI hypersensitivity site (DHS) in estrogen and tamoxifen-treated ENCODE50 Ishikawa 
cells (Figure 4a). In addition, in a Hi-C chromatin capture experiment in Hela S3 cells51, a 
chromatin interaction loop was observed between a segment containing the KLF5 promoter 
and the rs11841589/rs9600103 locus (P=0.004, Supplementary Figure 4).  
 
We further investigated the epigenetic landscape of a 16kb region around rs11841589 and 
rs9600103 that contained the SNPs most strongly associated with endometrial cancer, by 
analysis of three endometrial cancer cell lines: Ishikawa (homozygous for the rs9600103-A 
and rs11841589-G high-risk alleles and provides a comparison with the ENCODE data); 
ARK-2 (homozygous for the low-risk T alleles at both SNPs); and AN3CA (a non-KLF5 
expressing line that is homozygous for the high-risk alleles) (Supplementary Figure 5). We 
conducted formaldehyde-assisted identification of regulatory elements (FAIRE, to identify 
regions of open chromatin), and chromatin immunoprecipitation (ChIP) using antibodies 
against H3K4Me2 (marker of transcription factor binding52) and panH4Ac (marker of active 
chromatin). Although the anti-H4Ac ChIP did not display a consistent signal in the region, 
peaks in signals from FAIRE and anti-H3K4Me2 ChIP were specifically present in the KLF5-
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expressing lines and were co-located with the conservation peak and DHS from the 
ENCODE data at rs9600103, providing strong evidence for open chromatin and transcription 
factor binding at this site (Figure 4a). We then conducted chromatin conformation capture 
experiments for the KLF5-expressing Ishikawa endometrial cancer cells (Supplementary 
Figure 5) and found a significant interaction between the NcoI restriction fragment 
containing the rs11841589/rs9600103 risk loci SNPs and the promoter region of KLF5 
(Figure 4b).  
 
The regulatory nature of the region around rs11841589/rs9600103 was investigated using 
allele-specific luciferase reporter assays in Ishikawa cells (Figure 4c). Paired t-tests were 
used to compare the relationships between fragments containing the rs11841589 and 
rs9600103 alleles, and the pGL3-Promoter reporter vector (no insert) control 
(Supplementary Table 7). Fragments containing the rs9600103-T, rs11841589-T and 
rs11841589-G alleles had activity significantly lower than that of the pGL3-Promoter control 
(P≤0.014). In contrast, the construct containing the rs9600103-A risk allele had luciferase 
expression similar to the pGL3-Promoter control (P=0.23) and significantly higher than that 
of the corresponding rs9600103-T protective allele (P=0.02). These results suggest that the 
endometrial cancer risk tagged by rs11841589 is at least partly due to a regulatory element 
containing rs9600103, which interacts with the KLF5 promoter region, with the risk 
rs9600103-A allele likely associated with increased gene expression.  
In summary, this meta-analysis identified five novel endometrial cancer risk loci at genome-
wide significance, bringing the total number of common endometrial cancer risk loci 
identified by GWAS to seven (Figure 1). Together with other risk SNPs reaching study-wide 
significance32,53,54, these explain ~5.1% of the endometrial cancer familial relative risk. Novel 
endometrial cancer risk SNPs lie in likely enhancers predicted to regulate genes or miRNAs 
with known or suspected roles in tumorigenesis, and we specifically showed that a functional 
SNP at 13q22.1 may sit within a transcriptional repressor of KLF5. Our findings further clarify 
the genetic etiology of endometrial cancer, provide regions for functional follow-up, and add 
key information for future risk stratification models. 
URLs 
rmeta, http://cran.r-project.org/web/packages/rmeta/ 
The Cancer Genome Atlas (TCGA) http://www.cancergenome.nih.gov/ 
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Figure legends 
 
Figure 1: Endometrial cancer meta-analysis Manhattan plot 
Manhattan plot of –log10-transformed P-values from meta-analysis of 22 autosomes. There 
are seven loci surpassing genome-wide significance including two known loci: 15q21 
(CYP19A1) and 17q12 (HNF1B) and five novel loci: 6q22 (NCOA7, HEY2), 8q24 (MYC), 
13q22 (KLF5), 14q32 (AKT1, SIVA1), 15q15 (EIF2AK4, BMF).  
 
Figure 2: Forest plots of novel endometrial cancer risk loci 
The odds ratio and 95% confidence intervals of each study of the meta-analysis are listed 
and shown in the adjacent plot. The I2 heterogeneity scores (all <0.4) suggest that there is 
no marked difference in effects between studies. The SNPs represented are: a) rs11841589 
(13q22), b) rs13328298 (6q22), c) rs4733613 (8q24), d) rs17232730 (8q24, pairwise r2 0.02 
with rs4733613), e) rs937213 (15q15) and f) rs2498796 (14q32).  
 
Figure 3: Regional association plots for the five novel loci associated with 
endometrial cancer.  
The –log10 P-values from the meta-analysis and regional imputation for three GWAS and 
eight iCOGS groups are shown for SNPs at: a) 13q22.1, b) 6q22, c) & d) 8q24, e) 15q15 and 
f) 14q32.33. The SNP with the lowest P-value at each locus is labeled and marked as a 
purple diamond, and the dot color represents the LD with the top SNP. The blue line shows 
recombination rates in cM/Mb. All plotted SNPs are either genotyped or have an IMPUTE 
info score of more than 0.9 in all datasets. Although genome-wide significant results for the 
14q32.33 locus rely on imputed data, it should be noted that there is strong support from 
nearby genotyped markers. Supplementary Figure 6 displays similar regional association 
plots with a larger number of SNPs using a less stringent info score cut-off.  
 
Figure 4: The 13q22.1 endometrial cancer susceptibility locus 
a) Diagram showing the 16kb region around rs11841589, rs9600103 and correlated SNPs 
rs7981863, rs7988505 and rs7989799 (black marks), DNaseI hypersensitivity site (DHS) 
density signal in estrogen- and tamoxifen-treated ENCODE Ishikawa cells (Supplementary 
Note), and 100 vertebrates conservation. Vertical dotted line represents the position of 
rs9600103. FAIRE and ChIP assays for H3K4Me2 and H4Ac in endometrial cancer cell lines 
ARK-2 (rs9600103-TT), Ishikawa (rs9600103-AA) and AN3CA (rs9600103-AA) show 
evidence for enrichment of histone modifications.  
b) 3C experiment for KLF5-expressing Ishikawa cells. Relative interaction frequencies 
between an NcoI restriction fragment containing risk SNPs rs9600103 and rs11841589 (bait 
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fragment) and NcoI fragments across the KLF5 promoter region, plotted against fragment 
position on chromosome 13. NcoI restriction sites are displayed below the schematic of 
KLF5 transcripts. H3K4Me3 binding, indicative of promoters, from multiple ENCODE cell 
lines are also shown.. The graph represents three biological replicates. Error bars represent 
standard deviation. A significant interaction was seen with the fragment containing a KLF5 
transcriptional start site (fragment shaded in grey). 
c) Luciferase reporter assays to analyze the activity of 3kb fragments containing either 
rs9600103 or rs11841589 using the pGL3-Promoter vector in Ishikawa cells. Green arrows 
represent the low-risk alleles, and red arrows the high-risk alleles. Error bars represent the 
standard error of the mean (n=3). Luciferase activity for the rs9600103-A risk allele was 
more than double that of the rs9600103-T protective allele (P=0.018). There was no 
significant difference in luciferase activity between the rs11841589 alleles (Supplementary 
Table 7). 
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Table 1: Risk loci associated with endometrial cancer at P< 5×10−8 in the meta-analysis.  
 
Locus SNP Position 
Nearby 
gene(s) 
EA OA EAF 
All histologies Endometrioid histology 
Allelic OR 
(95%CI) 
P I
2
 
Allelic OR 
(95%CI) 
P I
2
 
Novel GWAS loci            
13q22.1 rs11841589 73,814,891 KLF5, KLF12 G T 0.74 1.15 (1.11-1.21) 4.83×10
−11
 0.19 1.16 (1.10-1.21) 6.01×10
−10
 0.00 
6q22.31 rs13328298 126,016,580 
HEY2, 
NCOA7 
G A 0.58 1.13 (1.09-1.18) 3.73×10
−10
 0.00 1.15 (1.11-1.20) 1.02×10
−11
 0.00 
8q24.21 rs4733613 129,599,278 MYC G C 0.87 0.84 (0.80-0.89) 3.09×10
−9
 0.00 0.84 (0.79-0.89) 7.70×10
−9
 0.09 
15q15.1 rs937213 40,322,124 
EIF2AK, 
BMF 
T C 0.58 0.90 (0.86-0.93) 1.77×10
−8
 0.36 0.90 (0.86-0.94) 2.22×10
−7
 0.30 
14q32.33 rs2498796 105,243,220 AKT1, SIVA1 G A 0.70 0.89 (0.85-0.93) 3.55×10
−8
 0.00 0.88 (0.85-0.92) 4.22×10
−8
 0.00 
Previously reported GWAS loci           
17q12 rs11263763 36,103,565 HNF1B A G 0.54 1.20 (1.15-1.25) 2.78×10
−19
 0.37 1.20 (1.15-1.25) 6.51×10
−17
 0.52 
15q21 rs2414098 51,537,806 CYP19A1 C T 0.62 1.17 (1.13-1.23) 4.51×10
−13
 0.00 1.18 (1.13-1.23) 2.48×10
−13
 0.00 
 
Positions in build 37; EA, Effect allele; OA, Other allele; EAF, effect allele frequency; I2, heterogeneity I2 statistic55. For all novel loci, the lead 
SNP was either directly genotyped or imputed with an information score of more than 0.9. HNF1B and CYP19A1 have been previously reported 
by Painter et al.8 and Thompson et al9.  
 
  
 18 
Table 2: Conditional analysis of 8q24 locus showing two independent association signals. 
 
SNP Position EA OA EAF 
Pairwise r
2 
with All histology meta-analysis Conditioning on rs4733613 Conditioning on rs17232730 
rs4733613 rs17232730 
Allelic OR 
(95%CI) P 
Allelic OR 
(95%CI) P 
Allelic OR 
(95%CI) P 
rs4733613 129,599,278 G C 0.87 - 0.02 0.84 (0.79-0.89) 5.64 × 10
−9
 - - 0.86 (0.81-0.91) 2.32 × 10
−7
 
rs17232730 129,537,746 G C 0.88 0.02 - 1.17 (1.10-1.24) 4.46 × 10
−7
 1.14 (1.08-1.22) 1.29 × 10
−5
 - - 
rs10088218* 129,543,949 G A 0.87 0.02 0.43 1.14 (1.07-1.20) 1.65 × 10
−5
 1.12 (1.05-1.18) 2.92 × 10
−4
 1.01 (0.91-1.12) 0.818 
 
 
Positions in build 37; EA, Effect allele; OA, Other allele; EAF, effect allele frequency. 
*rs10088218 is associated with ovarian cancer (all subtypes), with the association being more significant for cancers of serous histology. 
rs10088218-G is the risk allele for both endometrial cancer and ovarian cancer. 
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Online Methods 
 
Cases and controls were matched as summarized in Supplementary Table 1.Each sample 
set is described in the Supplementary Note. Supplementary Figure 1 illustrates the 
overall study design.  
 
 
Additional EC GWAS 
 
The National Study of Endometrial Cancer Genetics (NSECG) consisted of 925 histologically 
confirmed endometrial cancer cases from the UK; 86% with endometrioid-only histology. 
Genotyping was done using Illumina 660W Quad arrays.  
 
These cases were matched with 1,286 cancer-free controls from the UK1/CORGI12 and 
SP111 colorectal studies genotypedusing Illumina Hap550, Hap300 and Hap240S arrays, 
and. 1958 Birth Cohort55 controls from the Wellcome Trust Case Control Consortium 
(WTCCC2)13 genotyped using Illumina Infinium 1.2M arrays.  
 
 
Original endometrial cancer GWAS 
 
As described previously, cases with endometrioid histology were selected from two 
population studies; the UK Studies of Epidemiology and Risk factors in Cancer Heredity 
(SEARCH, n=681) and the Australian National Endometrial Cancer Study (ANECS, n=606), 
and genotypes generated using Illumina Infinium 610K arrays 10. Compared with our 
previous study 10, this meta-analysis analysed ANECS and SEARCH as two groups and 
included additional controls8,56.  SEARCH cases were compared with 2,501 controls from the 
National Blood Service (NBS) part of the WTCCC2 controls 13. ANECS cases were 
compared to controls recruited as part of the Hunter Community Study56 or Brisbane 
Adolescent Twin Study57, genotyped using Illumina Infinium 610K arrays.  
 
 
Phase 1 iCOGS genotyping 
 
For the iCOGS genotyping stage, 4,330 women with a confirmed diagnosis of endometrial 
cancer and European ancestry were recruited via 11 studies in Western Europe, North 
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America and Australia, collectively called the Endometrial Cancer Association Consortium 
(ECAC).  
 
Healthy female controls with European ancestry and known age at sampling were selected 
from controls genotyped by the Breast Cancer Association Consortium (BCAC)15 or Ovarian 
Cancer Association Consortium (OCAC)16 iCOGS projects. Eight case-control groups were 
matched based on geographical location, and principal components analysis (PCA) 
conducted; individuals who clustered outside the main centroid in pairwise plots of the first 
four PCs were excluded (Supplementary Figure 7). 
 
Cases and controls were genotyped on a custom Illuminia Infinium iSelect array with 
211,155 SNPs, designed by the Collaborative Oncological Gene-environment Study 
(iCOGS), a collaborative project involving four consortia. SNPs were included on this array 
based on promising regions of interest in previous breast, ovarian and prostate14 studies, 
and also the 1,483 top SNPs from our previous EC GWAS10  analysis. Cases and 
MoMaTEC controls were genotyped by Genome Quebec Innovation Center. BCAC and 
OCAC control samples were genotyped at four centres.  Raw intensity data files for all 
consortia were sent to the COGS data co-ordination centre at the University of Cambridge 
for centralized genotype calling and quality control (QC), so that all case and control 
genotypes were called using the same procedure. 
 
 
SNP genotyping arrays quality control 
 
Genotype calling was done using Illumina’s proprietary Gencall algorithm and Illumnus58. 
Duplicate samples displayed >99% concordance. Standard QC measures applied to 
genotyping arrays are described in our original GWAS 10 and include: genotypic call rate 
<0.95; deviation from Hardy-Weinberg Equilibrium (HWE) at P<10-6; visual inspection of 
cluster plots for most significant SNPs. For iCOGS, all endometrial cancer cases and 
MoMaTEC controls were genotyped by Genome Quebec Innovation Center. BCAC and 
OCAC control samples were genotyped at four centres.  Raw intensity data files for all 
consortia were sent to the COGS data co-ordination centre at the University of Cambridge 
for centralized genotype calling and QC, so that all case and control genotypes were called 
using the same procedure. Duplicate samples for QC showed a concordance of >99%. 
Samples were excluded based on the following measures: missingness >5%, heterozygosity 
rates ((N-O)/N) > 5 S.D from the mean, X chromosome heterozygosity rate (PLINK F-score) 
>0.2, and pairwise identity by descent (IBD) >0.1875 (cut-off for second-degree relatives). 
 21 
PCA was conducted using Eigenstrat59 software. Analysis was conducted using PLINK60, 
and R packages GenABEL and SNPMatrix61,62.  
 
 
Phase 2 NSECG genotyping 
 
A second genotyping phase consisted of assaying five SNPs with P<10-7 and IMPUTE info 
scores of >0.94 from the NSECG/ANECS/SEARCH/iCOGS meta-analysis; samples were 
NSECG cases and controls not previously been used in the NSECG GWAS or NSECG 
iCOGS. Genotyping was conducted using competitive allele-specific PCR (KASPar, 
KBiosciences) and the Fluidigm BioMarkTM HD System, using standard protocols. The 
genotyping call rate was >0.98 and there was a >0.985 concordance between different 
genotyping platforms (Supplementary Table 4). There was no significant deviation from 
HWE (P>0.05). Genotyping primers are listed in Supplementary Table 8.  
 
 
Genome-wide and regional imputation 
 
Genome-wide imputation for all SNP array generated data was conducted using IMPUTE 
v263 and 1000 Genomes project (2012 release) as reference panel. For the first-pass 
genome-wide analysis we pre-phased chromosomes using SHAPEIT64 to improve the 
computational speed.  Imputation was carried out separately for the each of the three GWAS 
studies (for each GWAS study the cases and controls were imputed together as a single 
dataset, using only SNPs which passed QC in both cases and controls) and for the iCOGS 
study (all studies within iCOGS were imputed together).  SNPs with MAF<0.1% were 
removed from all studies prior to imputation. Genome-wide imputation produced 9,594,066 
SNPs with MAF≥1% and info≥0.4 in at least one of the three GWAS and eight iCOGS 
groups. Of these, 8,308,423 SNPs met these criteria in all studies. The iCOGS genotyping 
array (~200,000 SNPs) is aimed at capturing previously prioritised cancer SNPs and not 
genome-wide coverage, but nonetheless 8,631,871 SNPs met MAF≥1% and info≥0.4 
criteria, of which 5,437,135 had info≥0.7 and 2,333,040 had info≥0.9. 
 
Regional imputation of regions of interest (1.5Mb region around SNPs with meta-analysis 
P<10-5) used both 1000 Genomes 2012 release and 196 high-coverage, whole genome-
sequenced UK individuals as reference panels as a means to improve imputation 
accuracy65. All SNPs reported in this study had an info score ≥0.9 in all datasets.  
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Association testing 
 
Association testing was done using SNPTEST v266 employing frequentist tests with a logistic 
regression model for each of the 11 groups as matched in Supplementary Table 1. There 
was little evidence of systematic over-dispersion of the test statistic from the quantile-
quantile plots (Supplementary Figure 2) and the genomic inflation λGC, calculated using all 
genotyped SNPs passing QC for the three GWAS. For iCOGS, 105,000 SNPs after LD-
pruning (r2<0.2) and >500kb from the 1,483 EC prioritized SNPs on the iCOGS were used. 
λGC was between 1.002 and 1.038 for each study. Conditional logistic regression analysis 
was conducted for each locus of genome-wide significance using SNPTEST to look for the 
presence of multiple independent association signals. This was done in a stepwise manner, 
first conditioning for the most significant SNP and subsequently for any SNPs that remained 
significant at Pcond<10
-4. Regional association plots (Figure 1, Supplementary Figure 6) 
were created using LocusZoom67.  
 
 
Meta-analysis 
 
Inverse variance, fixed effects meta-analysis of the 11 groups (three GWAS, eight iCOGS 
groups) was conducted using GWAMA68. The per allele effect size of each SNP in a 
particular study is represented by  (the log-odds ratio) and its standard error.  Inter-study 
differences are represented by the I2 heterogeneity score69,70. Forest plots of the genome-
wide significant loci (Figure 2) representing risk effects across different studies were made 
using rmeta.  A random-effects meta-analysis was also performed for SNPs with I2>0.3.  The 
results of the second replication phase (NSECG replication) were meta-analyzed in a 12-
way meta-analysis for the top 5 SNPs yielding a total of 7,737 EC cases and 37,144 
controls. 6,635 (86%) of the EC cases had endometrioid-only histology and association 
testing and meta-analysis were also conducted with just these samples.  
 
 
Bioinformatic analysis and functional annotation of genome-wide significant risk loci 
 
The five novel genome-wide significant loci and SNPs in LD (r2>0.7 in European 1000 
Genomes) were annotated using HaploregV271, RegulomeDB72 and data from ENCODE50 in 
Supplementary Table 6. This includes information such as promoter and enhancer histone 
marks, DHS, bound proteins, altered motifs, GENCODE and dbSNP annotations, 
RegulomeDB score and PhastCons conservation scores.  
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Bioinformatic analysis in Supplementary Figure 3 used datasets described by Hnisz et al. 
73 and Corradin et al. 74 to identify likely enhancers in a cell-specific context for the risk loci. 
Enhancer-gene interactions are predicted by identifying 'super-enhancers' (regions 
containing neighbouring H3K27Ac modifications) from 86 cell and tissue types and then the 
expressed transcript with transcription start site closest to the centre of the super-enhancer 
was assigned as the target gene. PresTIGE pairs cell-type specific H3K4Me1 and gene 
expression data from 13 cell types to identify likely enhancer-gene interactions. 
 
 
Endometrial-tissue expression quantitative trait loci (eQTL) analysis for associated 
SNPs using GTEx and TCGA data 
 
Publicly available data generated by the Genotype-Tissue Expression Project (GTEx)20 and 
The Cancer Genome Atlas (TCGA) were accessed to examine tissue-specific eQTLs. For 
GTEx, expression and genotype data were generated from 70 normal uteri from post-
mortem biopsies, using an Affymetrix Expression array and Illumina Omni 5M SNP array. 
GTEx provided processed results, evaluating association between genotype and expression 
data. The expression levels are represented as a rank normalized score. TCGA genotype 
and copy number variation (CNV) data were derived from Affymetrix 6.0 SNP arrays. 
Expression data were from RNAseq arrays (Illumina HiSeq and Illumina GA) for 458 
endometrial cancer tissues and 30 adjacent normal endometrial tissues. Association 
analyses for TCGA datasets were performed as follows. Genes within 500kb flanking our 
SNPs of interest were selected for analysis. Since there may be significant variation in 
tumour tissue copy number, somatic CNVs were taken into account by regressing gene 
expression to average copy number spanning the gene. Residual unexplained variance in 
gene expression was then regressed on the genotype of the lead SNP at each locus, using 
genotyped or imputed data. Statistical comparisons were subject to Bonferroni correction for 
number of tests (number of sample sets, and number of genes assessed). 
 
 
DNA and RNA extraction from cell lines 
 
Cell lines were from the laboratory of Dr David Church, acquired as gifts from Brittia Weigelt 
(currently at Memorial Sloan Kettering, USA), and Konstantin Dedes (University of Zurich, 
Austria), were routinely tested for mycoplasma contamination. Somatic mutation data 
generated previously matches that reported in publicly available resources and the literature, 
where available. Cells were snap frozen with dry ice after centrifugation, and DNA and RNA 
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extracted using DNeasy and RNeasy minikits (Qiagen). Nucleic acids were quantified using 
Nanodrop 2000 (ThermoScientific) spectrophotometry. 
 
 
Quantification of KLF5 expression in endometrial cancer cell lines 
 
Extracted RNA was treated with DNase 1, and complimentary DNA (cDNA) was reverse 
transcribed from RNA using the High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems). TaqMan Gene Expression Assays were used for KLF5 and GAPDH (details 
available from authors). The absolute expression of KLF5 was quantified using qRT-PCR 
using the ABI 7900HT cycler (Applied Biosystems), and the critical threshold was manually 
set at 0.2. Relative expression was calculated using the ΔΔCT method described by Livak 
and Schmittgen75, with GAPDH as an endogenous control.  
 
 
Formaldehyde-assisted identification of regulatory elements (FAIRE)  
 
Formaldehyde-Assisted Isolation of Regulatory Elements (FAIRE) was conducted using the 
method adapted from Giresi et al76. Briefly, cross-linking was done on a rocker at room 
temperature. 1% formaldehyde was added to ~108 cells for 5 minutes, and 115mM glycine 
added to inhibit cross-linking. For each cell line, a non-crosslinked control was prepared in 
parallel for all remaining steps. After two rinses with 4C phosphate buffered saline solution 
(PBS), cells were suspended in successive buffers: Lysis buffer I (50mM HEPES-KOH, 
140mM NaCl, 1mM EDTA, 10% glycerol, 0.5% NP-40, 0.25% tritonX-100); lysis buffer II 
(10mM tris-HCl, 200mM NaCl, 1mM EDTA, 0.5mM EGTA); lysis buffer III (10mM tris-HCl, 
2100mM NaCl, 1mM EDTA, 0.1% sodium deoxycholate, 0.5% N-lauroylsarcosine). Cells 
were incubated on a rocker at 4C for 10 minutes in each lysis buffer, thenspun down at 
1300 g for 5 minutes, and the supernatant removed. The cells were then sonicated using the 
Bioruptor in seven to fifteen 30-second cycles to generate fragments 100-1000 bp in size, 
and gel electrophoresis in 1% agarose used to confirm DNA fragment sizes. The DNA was 
extracted with a standard phenol/chloroform method and ethanol-precipitated. 50ng of DNA 
from paired crosslinked and non-crosslinked cells was analyzed in duplicate by SYBR-green 
quantitative PCR (qPCR) using primers at ~1kb intervals in the 13q22.1 region downstream 
of KLF5 (Supplementary Table 8). The ΔΔCt method31 was used to normalize results to the 
input DNA from non-crosslinked cells and then expressed relative to the Rhodopsin 
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promoter as negative control. For each experiment there were two replicates for the 
crosslinked cells and non-crosslinked controls, each performed on two occasions. 
 
 
Cross-linked Chromatin immunoprecipitation (ChIP)  
 
About 108 cells were cross-linked using 1% formaldehyde for 10 minutes. Glycine was used 
to stop the cross-linking, cells were then rinsed twice in PBS, and cell scrapers used to 
detach cells adhered to the Petri dish surface. Cells were then resuspended in lysis buffer 
(1% sodium dodecyl sulfate (SDS), 10mM EDTA (Ambion), 50mM Tris-HCl (Ambion)) 
incubated for 10 minutes, and then sonicated using the Bioruptor (Diagenode) in 7 to 15 30-
second cycles to generate fragments 1000-1500 bp in size. Gel electrophoresis in 1% 
agarose confirmed the size of the DNA fragments. The fragmented DNA was then diluted 
ten times to the immuno-precipitation dilution buffer (1% tritonX-100, 2nM EDTA, 20mM Tris-
HCl, 150mM sodium chloride and each cell line was separated into four tubes: input 
chromatin, no-antibody-control  and one tube for each antibody.  5ul of anti-dimethyl-histone 
H3 Lys4 (Millipore 07-030) and anti-acetyl-histone H4 (Millipore 06-866) were added to the 
antibody tubes and, along with the no-antibody-control, incubated overnight at 4C for 
immunoprecipitation. The input chromatin was kept refrigerated at 4C until the reverse 
cross-linking of day 2. Phenylmethylsulfonyl fluoride and protease inhibitor was added to the 
lysis buffer and IP dilution buffer to deactivate proteases, while sodium butyrate was added 
to these solutions to inhibit histone deacetylases. 5ul of protein A Dynabeads was added to 
each tube and incubated for 4 hours. A series of washes were done using 
Tris/Sucrose/EDTA (TSE) I (1% tritonX-100, 2mM EDTA, 20mM Tris-HCl, 150mM NaCl, 
0.1% SDS), TSE II (1% tritonX-100, 2mM EDTA, 20mM Tris-HCl, 500mM NaCl, 0.1% SDS), 
Buffer III (0.25M lithium chloride, 1mM EDTA, 10mM Tris-HCl, 1% tergitol-type NP-40, 1% 
sodium deoxycholate) and tris-EDTA (1X). 300ul of extraction solution (1% SDS 0.1M 
sodium bicarbonate) was added and Dynabeads were removed after a 30 minute incubation. 
Then 0.7 M NaCl was added and reverse cross-linking occurred overnight at 65C.  DNA 
was purified using the QIAquick PCR purification kit (Qiagen). 1ul of DNA was analyzed in 
duplicate or triplicate by SYBR green qPCR as above and the ΔΔCt method was used to 
identify areas with enrichment. For each experiment there were two replicates for each 
antibody along with the input and no-antibody control, each performed on two occasions. 
Primers used are listed in Supplementary Table 8.  
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Chromatin conformation capture (3C) 
 
Experiments were performed as described in Ghoussaini et al.77 , using the KLF5-
expressing Ishikawa endometrial cancer cell line from ATCC. The cell line was authenticated 
using a short tandem repeat (STR) profiling, and routinely tested for mycoplasma 
contamination (QIMR Berghofer in-house Support Services). Briefly, Ishikawa cell lines were 
crosslinked with 1% formaldehyde for 10 mins, quenched with 125mM glycine, washed with 
PBS and collected by scraping. Cells were lysed for 30 min on ice in 10mM Tris-HCl, pH 7.5, 
10mM NaCl, 0.2% Igepal with protease inhibitors and homogenized in a Dounce 
homogenizer. Nuclei were pelleted and resuspended in 1ml 1.2X restriction buffer (NEB 3.1) 
with 0.3% SDS for 1h at 37°C. 2% Triton X-100 was added then 1000U NcoI was added 3 
times over 24h at 37°C with shaking. The enzyme was inactivated, and digested DNA 
diluted 8X before ligation with 4000U of T4 DNA ligase overnight at 16°C. Crosslinks were 
reversed by proteinase K digestion at 65°C overnight, and the DNA purified by phenol–
chloroform extraction and ethanol precipitation. The final DNA pellet was dissolved in 10mM 
Tris (pH 7.5) and purified through Amicon Ultra 0.5 ml columns (Millipore). 3C interactions 
were quantified by SYTO9 qPCR (performed on a RotorGene 6000) using primers designed 
to amplify across ligated NcoI restriction fragments with one constant primer within the risk 
fragment (including rs11841589 and rs9600103) and a series of test primers within NcoI 
fragments spanning 76 kb of the KLF5 promoter region. BAC clones (RP11-81D9, RP11-
179I20) covering the region were digested with NcoI, ligated with T4 ligase and used 
determine PCR efficiency. 3C analyses were performed on three independent 3C libraries, 
with each data point in duplicate. Data were normalized to the signal from the BAC clone 
library and from a non-interacting chromosomal region using the ΔΔCt method with 
incorporated individual primer pair efficiencies. 
 
 
Luciferase reporter assays 
 
For luciferase reporter assays, the regions chr:13 73,810,509-73,813,452 around rs9600103 
and chr13:73,813,268-73,816,290 around rs11841589 were cloned into the pGL3-Promoter 
vector (Promega) to test for regulatory effects in Ishikawa cells. Ishikawa cells were selected 
because they express KLF5, showed evidence of a DHS, FAIRE and H3K4Me2 enrichment 
at rs9600103 and were readily transfectable. Site-directed mutagenesis was used so both 
the high- and low-risk alleles of rs9600103 and rs11841589 were tested. After sequencing to 
verify the correct insert sequences, cells were transiently co-transfected using lipofectamine 
with the appropriate pGL3-Promoter constructs, and the Renilla luciferase pGL4.75 vector 
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(Promega) as control for transfection efficiency. After 48 hours, luciferase activity was 
measured (Dual-Glo Luciferase Assay System, Promega), and after subtracting background 
from lipofectamine-only controls, firefly luciferase activity from the putative enhancer regions 
was normalized to the Renilla luciferase values for each sample. Levels of firefly luciferase 
activity were compared with a control plasmid consisting of an empty pGL3, and also a 
noncoding 2.2-kb stretch of plasmid sequence from the pENTR1A plasmid (Invitrogen) 
cloned into the pGL3-Promoter vector previously used as a length of DNA with no regulatory 
activity78. Luciferase activity experiments had three or four replicates, each performed on 
three occasions (total of 11 assays). Primers used are listed in Supplementary Table 8.  
 
ANOVA found significant differences in luciferase levels (P<0.0001, F:11.6) but no 
significant differences between replicates conducted on different days (P=0.91, F:0.09). 
There were no significant differences between the pENTR1A control and the empty pGL3-
Promoter vector (P=0.085); pGL3-Promoter vector was used as control. We conducted 
paired t-tests for all comparisons using the average of biological repeats, between the pGL3 
no insert, rs9600103-A, rs9600103-T, rs11841589-G and rs11841589-T fragments 
(Supplementary Table 7, results unadjusted for multiple comparisons).  
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Detailed Description of the Case and Control Sample Sets 
 
A summary of the studies included in the GWAS and both additional genotyping phases is shown in 
Supplementary Table 1, with additional details provided below. Supplementary Figure 1 provides a 
flow diagram of the overall study design. All studies were of women of European ancestry. All studies 
have the relevant IRB approval in each country in accordance with the principles embodied in the 
Declaration of Helsinki, and informed consent was obtained from all participants. A total of 7,737 
cases and 37,144 controls were included in this analysis. Cases and controls were matched based on 
geographical location and case-control clustering in principal components analysis (PCA) 
(Supplementary Figure 1).  
 
Endometrial cancer case and control GWAS Sample Sets: 
 
Quality control (QC) was applied to all GWAS sets, following standard QC approaches detailed in 
Spurdle et al
1
. Also see online methods.  
 
NSECG 
National Study of the Genetics of Endometrial Cancer (NSECG) cases were identified from 
collaborating clinicians throughout the UK from 2008 to 2013, taking care not to recruit from centres 
involved in SEARCH. Inclusion criteria were adenocarcinomas of the uterus presenting at 70 years of 
age or younger. Almost all cases were incident and sampled within 6 months of diagnosis. Peripheral 
blood was collected from each participant and DNA extracted using standard methods and the 
participants completed the associated questionnaire. Tumour histology was confirmed from routine 
hospital reports and further details of histopathology and other tumor pathology characteristic was 
abstracted from these clinical pathology reports. 925 samples were genotyped using the Ilumina 
660W Quads in the GWAS scan, 965 samples were genotyped in the phase 1 additional genotyping 
using iCOGS arrays, and a further 1195 were genotyped using KASPar and Fluidigm genotyping for 
the second phase. There was no overlap in samples used and all cases were of European ancestry.  
 
ANECS 
The Australian National Endometrial Cancer Study (ANECS) is an Australian population-
based case-control family study of cancer of the uterine corpus
2
. Women aged 18-79, newly 
diagnosed with histologically confirmed primary cancer of the endometrium between July 
2005 and December 2007 were identified through major hospitals nationally, and also from 
state-based cancer registries. Excluding women who could not be contacted (mostly due to 
death, illness or failure to contact), case participation rate was 63%. Participants completed 
a detailed questionnaire providing clinical and epidemiological information, including 
ethnicity of all four grandparents. Information on tumor pathology characteristics was 
abstracted in standardized format from clinical pathology reports for all patients. 606 ANECS 
samples all of endometrioid-only histology were used for the original endometrial cancer 
case-control GWAS and a further 538 were genotyped using iCOGS for the first additional 
genotyping phase.  
 
SEARCH 
The Studies of Epidemiology and Risk factors in Cancer Heredity (SEARCH) is an ongoing 
population-based study with cases ascertained through the Eastern Cancer Registration and 
Information Centre (http://www.ecric.org.uk). All women diagnosed with endometrial cancer 
between the ages of 18-69 years (average age of diagnosis 58 years) from August 2001 to 
September 2007 were eligible for inclusion. Approximately 54% of eligible patients have 
enrolled in the study. Women taking part in the study were asked to provide a 20ml blood 
sample for DNA analysis, and to complete a comprehensive epidemiological questionnaire. 
Controls were also drawn from SEARCH (http://ccge.medschl.cam.ac.uk/search/), but had 
no prior history of cancer at the time of recruitment. They were female, also between the 
ages of 18-69 at the time of recruitment and matched to cases in geographical profile. 
Approximately 35% of eligible controls enrolled in the study. All participants reported 
Caucasian ethnicity. Information on tumor pathology characteristics was provided by the 
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Eastern Cancer Registration and Information Centre and was derived from clinical pathology 
reports for all patients. 681 SEARCH samples with endometroid-only histology were used in 
the original GWAS and a further 773 non-overlapping cases were used in the iCOGS 
analysis.  
 
UK1/CORGI 
The UK1 Colorectal Tumour Gene Identification (CoRGI) is a GWAS for colorectal 
neoplasia3. The 894 controls matched with the NSECG cases were spouses or partners 
unaffected by cancer and without a personal family history (to second degree relative level) 
of colorectal neoplasia. Known dominant polyposis syndromes, HNPCC/Lynch syndrome or 
bi-allelic MUTYH mutation carriers were excluded. All cases and controls were of white UK 
ethnic origin. Genotyping was done on the Illumina Hap550 arrays.  
 
Scotland Phase 1 
Scotland Phase1 is a colorectal cancer GWAS4 with 1012 cancer-free population controls 
Known dominant polyposis syndromes, HNPCC/Lynch syndrome or bi-allelic MUTYH 
mutation carriers were excluded. Control subjects were sampled from the Scottish 
population NHS registers, matched by age (±5 years), gender and area of residence within 
Scotland. A subset of 392 controls from this dataset were matched with the NSECG GWAS 
cases and these were chosen based on case-control clustering on PCA. Genotyping was 
done on the Illumina Hap300 and Hap 240S arrays. 
 
QIMR 
The Queensland Institute of Medical Research (QIMR) control sample is a subsection of 
subjects recruited as part of the Brisbane Adolescent Twin Study5,6. Twins were recruited 
from schools in Brisbane, Australia and surrounding areas of southeast Queensland and 
were examined close to their 12th birthday. Blood was obtained from all twins and most 
parents. Parents were asked the ancestry of all eight great-grandparents of the twins. More 
than 95% of great-grandparents were identified as being of northern European ancestry, 
mainly from Britain and Ireland. This analysis used genotype data from parents and siblings 
only, extracted from an existing Illumina 610K BeadChip genome-wide association scan7 
and recalled using the Illuminus algorithm. After QC, 1846 QIMR controls were available for 
inclusion in the analysis. 
 
HCS 
The Hunter Community Study (HCS) is a population-based cohort study consisting of men 
and women aged 55-85 years of age in Newcastle, New South Wales, Australia8. 
Participants were randomly selected from the NSW State electoral roll (listing on the 
electoral roll is compulsory in Australia) and contacted between December 2004 and 
December 2007. Non-English speaking persons and those living in a residential aged-care 
facility were ineligible for participation in the study. Participants were asked to complete five 
self-report questionnaires as well as attend the HCS data collection centre so clinical 
measures could be obtained. In total, 44.5% of eligible controls agreed to participate in this 
study. Genotype data for this study were extracted from an existing Illumina 610K BeadChip 
genome-wide association study scan and recalled using the Illuminus algorithm. After QC, 
1237 HCS controls were available for inclusion in the analysis.  
 
WTCCC 
Controls utilized were genotyped as part of the Wellcome Trust Case Control Consortium 
(WTCCC2)
9
.  These controls are drawn from two sources: 2,674 controls from the 1958 
Birth Cohort (1958BC), a population-based study in the United Kingdom of individuals born 
in 1 week in 1958
10
; and 2,501 controls identified through the UK National Blood Service 
(NBS)
9
. 1958BC controls were matched with NSECG cases and the NBS controls were 
matched with SEARCH cases.  
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Phase 1 additional genotyping - iCOGS Case Sample Sets: 
 
All samples in this phase were genotyped as part of the Collaborative Oncological Gene-
environment Study (iCOGS) initiative on a custom Ilumina Infinium iSelect array. Cases from 
ANECS and SEARCH and NSECG were recruited as detailed above, and are non-
overlapping.  
 
BECS 
The Bavarian Endometrial Cancer Cases and Controls Study (BECS) is a single-center 
case-control study, conducted between 2002 and 2008, with the aim of investigating genetic 
and epidemiological risk factors for endometrial cancer. Cases were either incident cases 
referred to the University Hospital Erlangen by surrounding practitioners (66% of the case 
sample set), or prevalent cases that were outpatients in follow-up care approached within 
6.2 (±4.6 SD) years after treatment for primary endometrial cancer in the same hospital 
(34% of the case sample set). Epidemiological information was collected by a structured 
questionnaire completed during an interview and clinical data for the cases was obtained 
from clinical health records. 
 
CAHRES 
Details of the population selection process have been published previously for the Cancer 
Hormone Replacement Epidemiology Study (CAHRES)
11
. Formerly known as the Singapore 
and Sweden Breast/Endometrial Cancer Study (SASBAC), this population based case-
control study was conducted among Swedish women aged 50-74 years, who were residing 
in Sweden between January 1st 1994 and December 31st 1995. Endometrial cancer cases 
were identified through the nation-wide cancer registries in Sweden. All participants provided 
detailed questionnaire information. For endometrial cancer, histological specimens were 
reviewed and re-classified by the study pathologist. All participants reported Caucasian 
ethnicity.  
 
HJECS 
The Hannover-Jena Endometrial Cancer Study (HJECS), a hospital-based case-control 
study, included 250 German women, aged 31-89 years, who were recruited either at the 
Friedrich Schiller University of Jena or at Hannover Medical School after having been 
diagnosed with histologically confirmed primary incident endometrial carcinoma between 
2004 and 2010. Epidemiological data were obtained from questionnaires, and information on 
tumor stage and histology was obtained from pathology and clinical reports. Over 98% were 
of German descent. Interviews were conducted at either the Friedrich Schiller University of 
Jena or at Hannover Medical School, and peripheral blood was collected for the extraction of 
DNA from white blood cells. 
 
LES 
The Leuven Endometrial Study (LES) is a hospital based case-control study. Eligible cases, 
identified by active surveillance of electronic patient files at the Leuven University Hospital, 
were white women aged 27-80 years diagnosed with endometrial cancer. Clinical data for 
endometrial cancer patients were recorded during interview at the time of diagnosis, and 
from pathology reports. All medical records were reviewed by trained abstractors and 
pathology reports compatible with primary, invasive, epithelial endometrial adenocarcinoma 
of all stages (I –IV) and all grades were consulted. Participation rates exceeded 95% for 
cases. 
 
MECS  
The Mayo Endometrial Cancer Study (MECS) includes a clinic-based prospective collection 
of primary endometrial cases diagnosed from 2008 to 2011 and seen at Mayo Clinic 
Rochester with primary endometrial cancer diagnosed at age 18 and older. DNA was 
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isolated from white blood cells using a Qiagen isolation kit. DNA concentration was 
measured with picogreen. Clinical data were abstracted from electronic medical records and 
supplemented with a risk factor questionaire. Control data were obtained from Mayo Clinic 
OCAC controls (MAY) and BCAC controls (MCBCS). 
 
MoMaTEC 
Molecular Markers in Treatment of Endometrial Cancer (MoMaTEC) cases were recruited 
from an unselected patient population primarily treated for endometrial carcinoma at 
Haukeland University Hospital, Bergen during 2001-2009. This is the referral hospital for 
Hordaland county; the area is demographically well defined, with about 450,000 inhabitants, 
representing approximately 10% of the Norwegian population and with a similar incidence 
rate and prognosis as the total Norwegian population of endometrial cancers12–14. Clinical 
Information for cases regarding age, FIGO stage, histologic subtype, grade and prognosis 
was extracted from medical records. DNA was extracted from peripheral blood samples. 
 
NECS 
The Newcastle Endometrial Cancer Study (NECS) includes histologically confirmed 
endometrial cancer cases consecutively recruited from 1992 up to 2005 at the Hunter Centre 
for Gynaecological Cancer, John Hunter Hospital, Newcastle, New South Wales, Australia15. 
The final analysis included 194 endometrial cancer patients. Data on reproductive and 
environmental risk factors including ethnicity was collected using self reported 
questionnaires. Information regarding recurrence, stage, grade and histology of endometrial 
cancer was collected from medical records. Patients presenting at this hospital-based site 
were captured by ANECS recruitment from 2005 onwards.  
 
RENDOCAS 
The Registry of Endometrial Cancer in Sweden (RENDOCAS) is a hospital based case-
control study. Patients (n=520) who underwent surgery for endometrial cancer at Karolinska 
University hospital Solna, Sweden between 2008 and 2011 were included in the study. For 
each patient, the following was collected: blood and tumor samples; detailed family history 
and formulation of a pedigree where all suspected cancer cases were verified in medical 
records/pathology report if possible; questionnaire covering relevant environmental factors 
underlying endometrial cancer.  
 
Phase 1 additional genotyping - iCOGS Control Sample Sets: 
 
As indicated in Supplementary Table 1, iCOGS endometrial cancer case sample sets were 
matched with controls from the same countries and also clustered with cases in PCA 
(Supplementary Figure 2). Controls were genotyped using the same iCOGS array and data 
were largely drawn from healthy controls participating in the Breast Cancer Association 
Consortium (BCAC)16 part of the iCOGS initiative. Additional controls were from the Mayo 
Clinic via the Ovarian Cancer Association Consortium (OCAC)17,  and Norwegian female 
controls recruited in Bergen for use in the MoMaTEC case-control genotyping studies. 
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Endometrioid and non-endometrioid histology analysis 
 
Cases were defined as having endometrioid subtype based on pathology report of 
endometrioid histology only. Non-endometrioid subtypes included carcinosarcoma, clear 
cell, serous, mucinous, and tumours of mixed histology (any combination). 6,635 (86%) of 
the 7,737 endometrial cancer cases displayed endometrioid-only histology and association 
testing and meta-analysis was also conducted using endometrioid-only histology cases. The 
results of this analysis for the novel risk loci are shown in Table 1. Endometrioid-only phase 
1 meta-analysis (n=5,590) found only novel risk loci that were identified in the all histologies 
analysis (Table 1, Supplementary Table 2). Analysis of endometrial cancer cases that 
displayed non-endometrioid histology (in Phase 1, or the final meta-analysis) found no SNPs 
near genome-wide significance, as expected given the limited statistical power.  
 
Ishikawa and ECC-1 cells 
 
Results from Ishikawa and ECC-1 cells are listed separately in publicly available ENCODE18 
tier 3 data but STR-profiling has shown that these two cell lines are very similar19. Based on 
the results presented by Korch et al., the International Cell Line Authentication Committee 
(ICLAC) recommended in the 2013 Database of Cross-Contaminated or Misidentified Cell 
Lines that ECC-1 be re-identified as Ishikawa cells. Our in vitro functional analysis for the 
13q22 locus made use of our supply of Ishikawa cells for FAIRE and ChIP experiments and 
ECC-1 cells for luciferase reporter assays. Both cell lines displayed identical genotypes for 
rs9600103 and rs11841589, similar KLF5 expression levels, and 20x sequencing using the 
Ion AmpliSeq™ Comprehensive Cancer Panel confirmed that variants in Ishikawa and ECC-
1 are 90% concordant (based on 3,004 exonic SNVs in 409 cancer-related genes). In line 
with these findings and ICLAC recommendations, we have presented functional work on 
these cells as Ishikawa cells.  
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ECAC Study Collaborators 
 
The ANECS Group comprises: AB Spurdle, PM Webb, J Young (QIMR Berghofer Medical 
Research Institute); Consumer representative: L McQuire; Clinical Collaborators: NSW: S 
Baron-Hay, D Bell, A Bonaventura, A Brand, S Braye, J Carter, F Chan, C Dalrymple, A 
Ferrier (deceased), G Gard, N Hacker, R Hogg, R Houghton, D Marsden, K McIlroy, G 
Otton, S Pather, A Proietto, G Robertson, J Scurry, R Sharma, G Wain, F Wong; Qld: J 
Armes, A Crandon, M Cummings, R Land, J Nicklin, L Perrin, A Obermair, B Ward; SA: M 
Davy, T Dodd, J Miller, M Oehler, S Paramasivum, J Pierides, F Whitehead; Tas: P 
Blomfield, D Challis; Vic: D Neesham, J Pyman, M Quinn, R Rome, M Weitzer; WA: B 
Brennan, I Hammond, Y Leung, A McCartney (deceased), C Stewart, J Thompson; Project 
Managers: S O'Brien, S Moore; Laboratory Manager: K Ferguson; Pathology Support: M 
Walsh; Admin Support: R Cicero, L Green, J Griffith, L Jackman, B Ranieri; Laboratory 
Assistants: M O'Brien, P Schultz; Research Nurses: B Alexander, C Baxter, H Croy, A 
Fitzgerald, E Herron, C Hill, M Jones, J Maidens, A Marshall, K Martin, J Mayhew, E 
Minehan, D Roffe, H Shirley, H Steane, A Stenlake, A Ward, S Webb, J White. 
 
CHIBCHA (study of hereditary cancer in Europe and Latin America) collaborators 
include: Ma. Magdalena Echeverry de Polanco, Mabel Elena Bohórquez, Rodrigo Prieto, 
Angel Criollo, Carolina Ramírez, Ana Patricia Estrada, Jhon Jairo Suárez (Grupo de 
Citogenética Filogenia y Evolución de Poblaciones, Universidad del Tolima, Colombia); 
Augusto Rojas Martinez (Center for Research and Development in Health Sciences, 
Universidad Autónoma de Nuevo León, Monterrey, Mexico); Silvia Rogatto, Samuel Aguiar 
Jnr, Ericka Maria Monteiro Santos (Department of Urology, School of Medicine, UNESP - 
São Paulo State University, Botucatu, Brazil); Monica Sans, Valentina Colistro, Pedro C. 
Hidalgo, Patricia Mut (Department of Biological Anthropology, College of Humanities and 
Educational Sciences, University of the Republic, Magallanes, Montevideo, Uruguay); Angel 
Carracedo, Clara Ruiz Ponte, Ines Quntela Garcia (Fundacion Publica Galega de Medicina 
Xenomica, CIBERER, Genomic Medicine Group-University of Santiago de Compostela, 
Hospital Clinico, Santiago de Compostela, Galicia, Spain); Sergi Castellvi-Bel (Department 
of Gastroenterology, Institut de Malalties Digestives i Metabòliques, Hospital Clínic, Centro 
de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, IDIBAPS, 
University of Barcelona, Barcelona, Catalonia, Spain); Manuel Teixeira (Department of 
Genetics, Portuguese Oncology Institute, Rua Dr, António Bernardino de Almeida, Porto, 
Portugal). 
 
The NSECG Group comprises: Ian Tomlinson (Oxford University); M Adams, A Al-
Samarraie, S Anwar, R Athavale, S Awad, A Bali, A Barnes, G Cawdell, S Chan, K Chin,  P 
Cornes, M Crawford, J Cullimore, S Ghaem-Maghami, R Gornall, J Green, M Hall, M 
Harvey, J Hawe, A Head, J Herod, M Hingorani, M Hocking, C Holland, T Hollingsworth,J 
Hollingworth, T Ind, R Irvine, C Irwin, M Katesmark, S Kehoe, G Kheng-Chew, K Lankester, 
A Linder, D Luesley, C B-Lynch,V McFarlane, R Naik, N Nicholas, D Nugent, S Oates, A 
Oladipo, A Papadopoulos, S Pearson, D Radstone, S Raju, A Rathmell, C Redman, M 
Rymer, P Sarhanis, G Sparrow, N Stuart, S Sundar, A Thompson, S Tinkler, S Trent, A 
Tristram, N Walji, R Woolas. 
 
RENDOCAS investigators include: Annika Lindblom, Gerasimos Tzortzatos, Miriam Mints, 
Emma Tham, Ofra Castro, Kristina Gemzell-Danielsson. 
 
SEARCH collaborators include: Helen Baker, Caroline Baynes, Don Conroy, Bridget 
Curzon, Patricia Harrington, Sue Irvine, Craig Luccarini, Rebecca Mayes, Hannah Munday, 
Barbara Perkins, Daisy Pharoah, Radka Platte, Anne Stafford and Judy West. 
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BCAC and OCAC Study Collaborators (for control samples): 
 
The Australian Ovarian Cancer Study Group comprises: R Stuart-Harris; NSW‐ F 
Kirsten, J Rutovitz, P Clingan, A Glasgow, A Proietto, S Braye, G Otton, J Shannon, T 
Bonaventura, J Stewart, S Begbie, M Friedlander, D Bell, S Baron-Hay, A Ferrier 
(deceased), G Gard, D Nevell, N Pavlakis, S Valmadre, B Young, C Camaris, R Crouch, L 
Edwards, N Hacker, D Marsden, G Robertson, P Beale, J Beith, J Carter, C Dalrymple, R 
Houghton, P Russell, L Anderson, M Links, J Grygiel, J Hill, A Brand, K Byth, R Jaworski, P 
Harnett, R Sharma, G Wain; QLD- D Purdie, D Whiteman, B Ward, D Papadimos, A 
Crandon, M Cummings, K Horwood. A Obermair, L Perrin, D Wyld, J Nicklin; SA- M Davy, 
MK Oehler, C Hall, T Dodd, T Healy, K Pittman, D Henderson, J Miller, J Pierdes, A Achan; 
TAS- P Blomfield, D Challis, R McIntosh, A Parker; VIC- B Brown, R Rome, D Allen, P 
Grant, S Hyde, R Laurie M Robbie, D Healy, T Jobling, T Manolitsas, J McNealage, P 
Rogers, B Susil, E Sumithran, I Simpson, I Haviv, K Phillips, D Rischin, S Fox, D Johnson, S 
Lade, P Waring, M Loughrey, N O’Callaghan, B Murray, L Mileshkin, P Allan; V Billson, J 
Pyman, D Neesham, M Quinn, A Hamilton, C Underhill, R Bell, LF Ng, R Blum, V Ganju; 
WA- I Hammond, A McCartney (deceased), C Stewart, Y Leung, M Buck, N Zeps (WARTN); 
AOCS Management Group- DDL Bowtell, AC Green, G Chenevix-Trench, A deFazio, D 
Gertig, PM Webb.  
 
BSUCH collaborator: Peter Bugert 
 
ESTHER collaborators: Volker Arndt, Heiko Müller, Christa Stegmaier 
 
GENICA Network collaborators: Wing-Yee Lo, Christina Justenhoven, Ute Hamann, 
Thomas Brüning, Beate Pesch, Yon-Dschun Ko, Sylvia Rabstein, Anne Lotz, Christina 
Baisch, Hans-Peter Fischer, Volker Harth. 
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Supplementary Figure 1: Endometrial cancer meta-analysis flow diagram.  
This schematic figure illustrates the endometrial cancer case-control meta-analysis study 
design. The new NSECG GWAS was meta-analysed with a re-analysis of the original 
endometrial cancer GWAS (ANECS and SEARCH) and the iCOGS phase 1 genotypes 
(eight groups). This meta-analysis of 6,542 cases and 36,393 controls yielded 14 regions 
with SNPs P<10-5, of which five regions had SNPs P<10-7. These five SNPs were brought 
forward to the additional genotyping in a second phase, involving non-overlapping NSECG 
cases and controls, and were confirmed as novel genome-wide significant risk loci 
(P<5×10−8) in the overall meta-analysis of 7,737 cases and 37,144 controls.  
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Supplementary Figure 2: Quantile-quantile plots of the ranked trend test statistics for 
three GWAS and eight iCOGS groups.  
The –log10 transformed observed P-values (y-axis) were plotted against the expected P-
values under the null hypothesis (x-axis). The red line denotes the expectation under no 
deviation from the null hypothesis. The QQ-plots show little evidence of genomic inflation 
and the λGC for each study are: NSECG GWAS 1.020, ANECS GWAS 1.021, SEARCH 
GWAS 1.002, ANECS iCOGS 1.036, SEARCH iCOGS 1.016, NESCG iCOGS 1.038, MECS 
iCOGS 1.007, LES iCOGS 1.034, BECS iCOGS 1.030, MoMaTEC iCOGS 1.034, CAHRES 
RENDOCAS iCOGS 1.037. For the three GWAS, all genotyped SNPs passing QC are 
displayed. For iCOGS, 105,000 SNPs after LD-pruning (r2<0.2) and >500kb from the 1,483 
endometrial cancer prioritized SNPs on the iCOGS are displayed.  
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Supplementary Figure 3: Genetic landscape of novel endometrial cancer associated regions.  
Plots for novel risk loci at a) 13q22.1, b) 6q22.31, c) 8q24.21, d) 15q15 and e) 14q32. SNPs in strong LD (r2 > 0.7) with the lead endometrial 
cancer risk SNP have been plotted for each region and the lead SNP denoted in green. The second, independently associated SNP found at 
8q24.21 after conditioning on the lead SNP is denoted in red (c). Previously reported cancer risk SNPs identified by GWAS at 8q24 are shown 
in blue (c), none of which are in LD (r2≤0.02) with endometrial cancer risk SNPs. Likely enhancers identified by Hnisz et al.20 and PresTIGE21 
that overlap endometrial cancer risk associated SNPs are depicted as colored bars, where the color of the likely enhancer matches the 
schematic of its predicted target gene, as determined by correlations with gene expression. As described in Online Methods Hnisz et al. 
predicted enhancer-gene interactions by identifying 'super-enhancers' (regions containing neighboring H3K27Ac modifications) from 86 cell and 
tissue types and then the expressed transcript with transcription start site closest to the centre of the super-enhancer was assigned as the 
target gene. PresTIGE pairs cell-type specific H3K4Me1 and gene expression data from 13 cell types to identify likely enhancer-gene 
interactions. Additional tracks include: Histone modifications associated with promoters (H3K4Me3) and enhancers (H3K4Me1 and H3K27Ac) 
from seven ENCODE Project cell types; DNaseI hypersensitivity sites (DHS) and transcription factor (TF) binding identified in 125 and 91 
ENCODE Project cell types, respectively; DHS identified in Ishikawa endometrial cancer cells using DMSO vehicle and under estrogen (E2) 
stimulation are shown; transcription factor binding regions in Ishikawa cells that encompass endometrial cancer risk SNP loci are also 
displayed. For all risk loci, endometrial cancer risk associated SNPs co-locate with at least one enhancer predicted by cell-type specific 
analysis, implicating the following genes/transcripts as worthy of investigation: a) KLF5; b) HEY2, NCOA7; c) MYC, MIR1204, MIR1205, 
MIR1207, MIR1208; d) BMF, GPR176, SRP14, LOC100131089; e) AKT, ADSSL1, INF2, ZBTB42, SIVA1. For four loci (a, c, d and e), likely 
enhancers overlap with at least one region displaying evidence of regulatory activity (DHS and/or TF binding) in the single endometrial cancer 
cell line (Ishikawa) assayed by ENCODE.   
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Supplementary Figure 4: Hi-C chromatin capture of 13q22 locus in Hela S3 cells. a) 
5Kb KR normalized contact matrix in Hi-C experiment for HeLa S3 cells was used to 
represent the interaction pattern between KLF5 and risk locus rs11841589/rs960010322. A 
loop was anchored at the KLF5 promoter and the risk locus (see b) for the small 
topologically associated domain and the red arrow for loop anchor), which indicated distal 
cis-regulatory element within the risk locus. The interaction between the 
rs11841589/rs9600103 risk locus with the KLF5 promoter was the strongest interaction 
observed out of the 262 protein-coding genes on chromosome 13 (P=0.004). The color 
scheme in the contact matrix is KR normalized score, with the black indicating a strong 
interaction.  
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Supplementary Figure 5: Quantification of KLF5 expression in endometrial cancer cell 
lines.  Expression of KLF5 in 11 endometrial cancer cell lines as described in Online 
methods using qRT-PCR, expression levels on the x-axis are relative to KLF5 expression in 
Ishikawa cells using the ddCT method.  
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Supplementary Figure 6: Regional association plots for the five novel loci associated 
with endometrial cancer. 
The -log10 P values from the meta-analysis and regional imputation for NSECG, ANECS, 
SEARCH, and eight iCOGS groups are shown for SNPs at: a) 13q22.1, b) 6q22, c) & d) 
8q24, e) 15q15 and f) 14q32.33. The SNP with the lowest P value at each locus is labelled 
and marked as a purple diamond, and the dot color represents the LD with the top SNP. The 
blue line shows recombination rates in cM/Mb. Compared with Figure 2, more SNPs are 
displayed in these plots. SNPs with info scores of more than 0.6 in iCOGS and more than 
0.9 in NSECG, ANECS, and SEARCH are included.  
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Supplementary Figure 7: Principal Components Analysis (PCA) of three GWAS and 
eight iCOGS studies.  
Plots of the first two principal components (PCs) in each study. Endometrial cancer cases 
are represented by blue dots, whereas controls are in black. Samples were excluded if they 
clustered away from the centroid in the first four PCs and these are plots of the samples 
used in the analysis.  
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Supplementary Table 1: Endometrial cancer case and control sample sets
Study Case sampling frame Control sampling frame Genotyping Platform
Endometrial 
Cancer Cases
Endometoid 
histology
Controls
New Endometrial Cancer GWAS
NSECG UK National Study of Endometrial Cancer Genetics UK; population based cases Illumina660WQuads 925 795
UK1-CORGI
UK Colorectal Tumour Gene Identification 
Consortium
England; spouses and partners of cases with no personal or 
family history of colorectal neoplasia
Illumina Hap550 894
SP1
Scotland1 Scotland; cancer free controls from NHS registers
Illumina HumanHap300 
Illumina HumanHap240S
392
BC58
UK 1958 Birth Cohort
UK; population based controls, born within one week in 
1958
Illumina 1.2M 2,674
Original Endometrial Cancer GWAS
ANECS Australian National Endometrial Cancer Study Australia; population based cases Illumina 610K 606 606
QIMR
Queensland Institute of Medical Research Australia; parents of participants in adolescent twin study Illumina 610K 1,846
HCS Hunter Community Study Australia; population-based controls Illumina 610K 1,237
SEARCH
UK Studies of Epidemiology and Risk factors in 
Cancer Heredity
England; population based cases via cancer registries, age 
<69
Illumina 610K 681 681
NBS
UK; population based controls identified through National 
Blood Service
Illumina 1.2M 2,501
iCOGS Genotyping Sample Sets (Phase 1 additional genotyping)
ANECS Australian National Endometrial Cancer Study Australia; population based cases Illumina Infinium iSelect 373 217
NECS Newcastle Endometrial Cancer Study Australia;  hospital-based cases Illumina Infinium iSelect 165 116
ABCFS Australian Breast Cancer Family Study Australia; from electoral rolls Illumina Infinium iSelect 443
AOCS Australian Ovarian Cancer Study Australia; population-based, from electoral rolls Illumina Infinium iSelect 817
MCCS Melbourne Collaborative Cohort Study  Australia; random sample from initial cohort Illumina Infinium iSelect 437
5 SEARCH
UK Studies of Epidemiology and Risk factors in 
Cancer Heredity
England; population based cases England; population based controls Illumina Infinium iSelect 773 620 7,510
NSECG National Study of Endometrial Cancer Genetics England; population based cases Illumina Infinium iSelect 965 839
BBCS British Breast Cancer Study
UK; friend, sister-in-law, daughter-in-law or other non-
blood relative of breast cancer case
Illumina Infinium iSelect 1,353
SBCS Sheffield Breast Cancer Study
UK; women attending Sheffield Mammography Screening, 
with no breast lesion
Illumina Infinium iSelect 835
UKBGS UK Breakthrough Generations Study UK; women without breast cancer selected from BGS cohort Illumina Infinium iSelect 449
MECS Mayo Endometrial Cancer Study USA; Clinic based cases Illumina Infinium iSelect 221 163
MCBCS Mayo Clinic Breast Cancer Study
USA; Cancer-free women presenting for general medical 
examination
Illumina Infinium iSelect 1,762
MAY Mayo Clinic Ovarian Cancer Case-Control Study
USA; Cancer-free women presenting for general medical 
examination
Illumina Infinium iSelect 593
LES Leuven Endometrial Cancer Study Belgium; hospital based cases Illumina Infinium iSelect 321 219
LMBC Leuven Multidisciplinary Breast Centre Belgium; controls from blood donors Illumina Infinium iSelect 1,382
BECS/HJECS
Bavarian Endometrial Cancer Study/Hannover-Jena 
Endometrial Cancer Study
Germany; hospital-based cases, population-based cases Illumina Infinium iSelect 137 112
BBCC Bavarian Breast Cancer Cases and Controls
Germany;  healthy women >55yrs from newspaper 
advertisement
Illumina Infinium iSelect 441
BSUCH
Breast Cancer Study of the University Clinic 
Heidelberg
Germany; female blood donors Illumina Infinium iSelect 920
ESTHER ESTHER Breast Cancer Study Germany; random sample from routine health check-up Illumina Infinium iSelect 486
GC-HBOC
German Consortium for Hereditary Breast & Ovarian 
Cancer
Germany; KORA study Illumina Infinium iSelect 138
GENICA
Gene Environment Interaction and Breast Cancer in 
Germany
Germany; random address sample Illumina Infinium iSelect 420
MARIE Mammary Carcinoma Risk Factor Investigation Germany; randomly drawn from population registries Illumina Infinium iSelect 1,712
MoMaTEC
Molecular Markers in Treatment of Endometrial 
Cancer
Norway; population based cases Norway; female blood donors Illumina Infinium iSelect 599 505
NBCS Norwegian Breast Cancer Study
Norway; attendees at Norwegian Breast Cancer Screening 
Program
Illumina Infinium iSelect 234
CAHRES Cancer Hormone Replacement Epidemiology Sweden; population based cases Sweden; population based controls Illumina Infinium iSelect 543 512 1,345
RENDOCAS Registry of Endometrial Cancer in Sweden Sweden; hospital based cases Illumina Infinium iSelect 233 205
KARBAC Karolinska Breast Cancer Study Sweden; blood donors Illumina Infinium iSelect 585
pKARMA
Karolinska Mammography Project for Risk Prediction 
of Breast Cancer
Sweden; cancer-free participants of mammography 
screening
Illumina Infinium iSelect 4,987
NSECG genotyping (Phase 2 additional genotyping)
NSECG National Study of Endometrial Cancer Genetics UK; population based cases KASPar, Fluidigm 1,195 1,045
UK1/CORGI
UK Colorectal Tumour Gene Identification 
Consortium
England; spouses and partners of cases with no personal or 
family history of colorectal neoplasia
KASPar, Fluidigm 751
OVERALL META-ANALYSIS TOTAL 7,737 6,635 37,144
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Supplementary Table 2: Meta-analysis after regional imputation for risk loci P<10-5 identified by meta-analysis of GWAS and iCOGS datasets
SNP Position EA OA Allelic OR (95%CI) P RE OR (95%CI)*** RE P I
2
SNP Position EA OA Allelic OR (95%CI) P RE OR (95%CI)*** RE P I
2
13q22 KLF5, KLF12 rs11841589 73,814,891 G T 1.16 (1.11-1.21) 6.89E-11 - - 0.25 rs11841589 73,814,891 G T 1.16 (1.11-1.21) 6.89E-11 - - 0.25
6q22 NCOA7, HEY2 rs2747714 126,007,620 A G 1.13 (1.08-1.17) 3.35E-09 - - 0.00 rs13328298 126,016,580 G A 1.13 (1.08-1.17) 2.78E-09 - - 0.00
8q24 MYC rs4733613 129,599,278 G C 0.84 (0.79-0.89) 5.64E-09 - - 0.02 rs4733613 129,599,278 G C 0.84 (0.79-0.89) 5.64E-09 - - 0.02
15q15 EIF2AK, BMF rs937213 40,322,124 T C 0.90 (0.86-0.93) 3.81E-08 0.90 (0.85-0.94) 8.35E-06 0.41 rs937213 40,322,124 T C 0.90 (0.86-0.93) 3.81E-08 0.90 (0.85-0.94) 8.35E-06 0.41
14q32 AKT1, SIVA1 rs3001371 105,242,831 C T 0.89 (0.85-0.93) 1.33E-07 - - 0.00 rs2498796 105,243,220 G A 0.89 (0.85-0.93) 8.66E-08 - - 0.02
12q24 SH2B3, ATXN2 rs3184504 111,884,608 C T 1.11 (1.07-1.15) 2.16E-07 - - 0.00 rs3184504 111,884,608 C T 1.11 (1.07-1.15) 2.16E-07 - - 0.00
17q21 SKAP1 rs3944039 46,205,070 C T 1.10 (1.06-1.15) 1.63E-06 1.10(1.04-1.17) 0.001364 0.50 rs1452666 46,307,750 C T 1.11 (1.06-1.15) 9.49E-07 1.10(1.04-1.17) 7.41E-04 0.48
2p16 BCL11A rs6732518 60,708,597 T C 1.11 (1.06-1.16) 2.26E-06 0.00 rs7579014 60,707,894 A G 1.11 (1.07-1.16) 5.34E-07 0.00
12p12 SSPN rs17467365 26,431,039 C T 1.27 (1.15-1.41) 2.82E-06 1.29 (1.13-1.46) 9.97E-05 0.33 rs17467365 26,431,039 C T 1.27 (1.15-1.41) 2.82E-06 1.29 (1.13-1.46) 9.97E-05 0.33
3q13 LSAMP rs4378954 115,650,448 C T 1.16 (1.09-1.24) 7.20E-06 1.17 (1.08-1.27) 2.05E-04 0.31 rs4378954 115,650,448 C T 1.16 (1.09-1.24) 7.20E-06 1.17 (1.08-1.27) 2.05E-04 0.31
9q31 KLF4 rs4978670 110,826,546 A G 0.91 (0.88-0.95) 7.33E-06 - - 0.20 rs4978670 110,826,546 A G 0.91 (0.88-0.95) 7.33E-06 - - 0.20
8q21 STAU2 rs4237005 74,391,780 G A 0.88 (0.83-0.93) 8.02E-06 - - 0.00 rs4237005 74,391,780 G A 0.88 (0.83-0.93) 8.02E-06 - - 0.00
11q13 CCDC88B, RPS6KA4 rs71456310 64,128,494 C T 1.14  (1.08-1.21) 8.69E-06 - - 0.00 rs12808002 64,110,932 C T 1.14 (1.08-1.20) 2.18E-06 - - 0.00
3q21 EEFSEC rs3021461 128,095,652 G A 0.90 (0.86-0.94) 9.96E-06 0.91 (0.85-0.96) 0.001909 0.41 rs3021461 128,095,652 G A 0.90 (0.86-0.94) 9.96E-06 0.91 (0.85-0.96) 0.001909 0.41
Positions in build 37; EA, effect allele; OA, other allele; P, P-value; I2, heterogeneity I2 statistic. 
*Top SNPs from meta-analysis were genotyped in iCOGS, and genotyped or imputed in the GWAS datasets. 
** Imputed SNPs (in bold) are only included if information score was >0.9 in all datasets. 
*** Random effects (RE) meta-analysis was done for SNPs with I2 >0.3. OR and P-values are reported.
Locus Nearby gene(s)
Top SNP in meta-analysis* Top SNP after regional imputation**
Supplementary Table 3: Overall meta-analysis including additional genotyping from Phase 2
EA OA Case EAF Control EAF Allelic OR (95%CI) P I
2
Case EAF Control EAF Allelic OR (95%CI) P
13q22 KLF5, KLF12 rs11841589 73,814,891 G T 0.757 0.729 1.16 (1.11-1.21) 6.89E-11 0.25 0.741 0.723 1.10 (0.91-1.33) 0.323 4.83E-11
6q22 NCOA7, HEY2 rs13328298 126,016,580 G A 0.600 0.573 1.13 (1.08-1.17) 2.78E-09 0.00 0.616 0.569 1.22 (1.02-1.46) 0.032 3.73E-10
8q24 MYC rs4733613 129,599,278 G C 0.856 0.877 0.84 (0.79-0.89) 5.64E-09 0.02 0.853 0.867 0.89 ( 0.74-1.08) 0.219 3.09E-09
15q15 EIF2AK, BMF rs937213 40,322,124 T C 0.553 0.582 0.90 (0.86-0.93) 3.81E-08 0.41 0.549 0.570 0.92 (0.81-1.05) 0.524 1.77E-08
14q32 AKT1, SIVA1 rs2498796 105,243,220 G A 0.677 0.705 0.89 (0.85-0.93) 8.66E-08 0.02 0.681 0.702 0.91 (0.79-1.04) 0.177 3.55E-08
Positions in build 37; EA, Effect allele; OA, Other allele; EAF, effect allele frequency; I
2
, heterogeneity I
2
 statistic. 
Overall P
All SNPs are either typed or imputed with information score >0.9 in all arrays including iCOGS; phase 2 NSECG genotyping was performed using KASPar (rs4733613, rs937213, rs2498796) or Fluidigm (rs13328298, 
rs11841589)
Locus Nearby gene(s) SNP Position
Risk estimates from GWAS+iCOGs meta-analysis Risk estimates from Phase 2 NSECG genotyping
Supplementary Table 4: Genotyping concordance rates for different platforms in quality control duplicates
Platform1 Platform2 Samples SNPs
KASPar Fluidigm 491 2 0.988
KASPar Illumina 660W 23 6 0.986
KASPar Illumina iSelect 9 3 1.000
% Concordance: number of concordant genotypes were counted and divided by the total. Duplicate samples were excluded from all analysis. 
Genotyping Overlapping
% Concordance
Supplementary Table 5: Endometrial tissue eQTL: association between GWAS risk loci genotypes and transcript levels of nearby genes
Locus GWAS SNP Gene
GTEx 
Normal 
Uterus P
TCGA 
Adjacent 
Normal 
RNASeq P
TCGA 
Tumor 
RNASeq P
n=70 n=30 n=458
13q22.1 rs11841589 KLF5 0.88 0.27 0.02
KLF12 0.39 0.72 0.32
PIBF1 0.80 0.83 0.96
DIS3 0.52 0.17 0.36
BORA 0.71 - -
6q22.31 rs13328298 HEY2 0.14 0.73 0.01
NCOA7 0.05 0.31 0.98
HDDC2 - 0.12 0.24
TPD52L1 0.83 0.005 0.14
HINT3 0.35 0.57 0.41
TRMT11 - 0.84 0.29
8q24.21 rs4733613 MYC 0.98 0.16 0.38
PVT1 0.12 0.45 0.45
POU5F1B 0.26 0.79 0.85
rs17232730 MYC 0.51 0.17 0.23
PVT1 0.65 0.75 0.87
POU5F1B 0.05 0.64 0.15
15q15.1 rs937213 EIF2AK4 0.10 0.73 0.11
SRP14 0.40 0.53 0.07
BMF 0.90 0.27 0.61
BUB1B 0.44 0.003 0.62
PAK6 - 0.06 0.96
GPR176 0.32 0.37 0.29
THBS1 0.61 0.93 0.48
FSIP1 0.42 0.62 0.48
C15orf56 - 0.26 0.15
PLCB2 0.52 0.38 0.05
C15orf52 1.00 0.69 0.13
PHGR1 0.51 - -
DISP2 0.12 0.58 0.19
KNSTRN - - -
IVD 0.63 0.87 0.94
BAHD1 0.15 0.52 0.03
CHST14 0.86 0.01 0.57
14q32.33 rs2498796 AKT1 0.01 0.09 0.12
SIVA1 0.06 0.02 0.50
ZBTB42 0.49 0.15 0.008
INF2 0.98 0.85 0.20
ADSSL1 0.01 0.95 0.63
PLD4 0.74 0.05 0.86
TMEM179 - - -
AHNAK2 0.29 0.27 0.61
C14orf79 0.62 0.16 0.76
CDCA4 0.44 0.71 0.76
GPR132 0.26 0.46 0.66
C14orf180 0.58 0.92 0.96
JAG2 0.88 0.14 0.13
NUDT14 0.89 0.10 0.43
CEP170B 0.55 - -
BRF1 0.72 0.06 0.14
BTBD6 0.89 0.20 0.93
SNPs within 500kb of the top SNP were also analysed and we did not find any 
SNPs in these loci that were robustly associated with the expression of nearby 
genes. 
GTEx, Genotype Tissue Expression Project; TCGA, The Cancer Genome Atlas 
(TCGA).
"-" denotes expression data not present in this database.  See Online Methods.
After Bonferroni correction for number of tests (number of SNPs investigated 
= 6, number of sample sets=3, and number of genes assessed - up to 48), no 
associations were considered statistically signficant.
Supplementary Table 6: Functional annotation of SNPs in LD with GWAS risk loci (r2>0.7 in 1000 Genomes EUR) from Haploreg, RegulomeDB and ENCODE
Promoter Enhancer
13q22 73,811,879 0.98 rs9600103 A T 0.28
AP-1, Elf3, 
GR,PRDM1,SIX5
13q22 73,812,141 0.98 rs7981863 C T 0.28 Rad21,SMC3
13q22 73,813,435 0.98 rs7988505 C G 0.27
CDP,Foxa, 
Nanog,Sox
13q22 73,813,436 0.99 rs7989799 T A 0.27
13q22 73,813,982 0.75 rs9592895 T C 0.33 NHEK DMRT7,SIX5
13q22 73,814,891 - rs11841589 G T 0.28 Pou2f2
6q22 125,985,934 0.72 rs1832937 G A 0.55 Sox
6q22 125,988,964 0.96 rs1832938 G C 0.56
Hand1,Pou2f2, 
STAT
6q22 125,991,507 0.87 rs12527010 G A 0.54 H1 9 altered motifs
6q22 125,991,715 0.97 rs9491471 C T 0.56 H1 HRPEpiC 4 altered motifs
6q22 125,992,553 0.86 rs1418637 A G 0.59 H1 MAFF,MAFK 5 altered motifs
6q22 125,992,810 0.97 rs1343120 A G 0.56 4 altered motifs
6q22 125,993,202 0.97 rs4897151 T G 0.56 Nr2f2
6q22 125,994,080 0.96 rs6940748 C T 0.57 RWPE1 4 altered motifs
6q22 125,994,708 0.97 rs1935772 T C 0.56 AP-1,Sin3Ak-20
6q22 125,994,753 0.97 rs202061058 C CCAA 0.56
BRCA1,HNF1, 
STAT
6q22 125,995,134 0.97 rs6904069 G A 0.56 VDR
6q22 125,995,467 0.84 rs2226158 G A 0.53 HAc LBP-1
6q22 125,995,503 0.93 rs2211418 G A 0.55 FibroP,HAc
6q22 125,995,533 0.97 rs2211419 A G 0.56 FibroP 4 altered motifs
6q22 125,995,549 0.97 rs2211420 T C 0.56 FibroP STAT,Tel2
6q22 125,996,185 0.97 rs1418951 A G 0.56 CTCF
6q22 125,996,475 0.93 rs1935773 A G 0.55 H1 HRPEpiC RREB-1,Sp4
6q22 125,996,661 0.93 rs1935774 C T 0.55 CEBPB,CTCF,p300
6q22 125,997,436 0.93 rs1832979 A G 0.55
6q22 125,997,444 0.97 rs1832980 T G 0.56 6 altered motifs
EUR AF
Histone marks
DHS Bound proteins Altered MotifsAltLocus
Position 
(hg19)
LD SNP Ref
6q22 125,998,186 0.97 rs6569435 T C 0.56
6q22 125,998,286 0.96 rs11443856 T TC 0.56 4 altered motifs
6q22 125,999,674 0.86 rs2326292 G A 0.59 H1 Crx,Gsc,Otx2
6q22 125,999,768 0.97 rs1418642 G A 0.56 H1 4 altered motifs
6q22 125,999,854 0.97 rs1418641 C T 0.56 H1 4 altered motifs
6q22 125,999,866 0.97 rs1418640 G A 0.56 H1
6q22 125,999,940 0.96 rs1418639 C T 0.56 H1 HEN1
6q22 126,000,162 0.97 rs4895798 A G 0.56 H1 4 altered motifs
6q22 126,000,599 0.97 rs8180614 G C 0.56 H1
6q22 126,001,064 0.97 rs1954360 A G 0.56 H1
Jurkat, SK-
N-MC
6q22 126,001,423 0.97 rs1954361 C G 0.56 SF1,STAT
6q22 126,001,568 0.97 rs9321050 A G 0.56
Arid5a,CEBPA, 
HDAC2
6q22 126,002,400 0.97 rs4897152 A G 0.56 4 altered motifs
6q22 126,002,774 0.97 rs1935979 A G 0.56 Ik-1
6q22 126,003,403 0.97 rs4897153 A G 0.56 GR
6q22 126,003,603 0.96 rs201652751 C CCT 0.56 p300
6q22 126,004,124 0.96 rs9401843 T C 0.56 4 altered motifs
6q22 126,004,193 0.82 rs80303782 C T 0.52 H1-hESC POL24H8 HMG-IY,Pax-4
6q22 126,004,194 0.86 rs76407388 A G 0.53 H1-hESC POL24H8 Pax-4
6q22 126,004,197 0.94 rs28629380 A G 0.56 H1-hESC POL24H8 Pax-4
6q22 126,004,468 0.94 rs5879788 T TC,TT 0.56
6q22 126,004,720 0.97 rs1739367 G T 0.56 FOXA1,GATA3 5 altered motifs
6q22 126,004,883 0.97 rs1777194 G A 0.56 18 altered motifs
6q22 126,004,935 0.97 rs2747724 G A 0.56 Obox6
6q22 126,005,197 0.96 rs2797154 A G 0.56
6q22 126,005,310 0.97 rs1739352 T C 0.56 4 altered motifs
6q22 126,005,767 0.97 rs983543 G A 0.56 12 altered motifs
6q22 126,006,861 0.95 rs1777195 A C 0.44 7 altered motifs
6q22 126,007,018 0.97 rs1418948 C T 0.44 Ets
6q22 126,007,401 0.95 rs1777197 G A 0.43 11 altered motifs
6q22 126,007,409 0.95 rs1739366 T C 0.43 7 altered motifs
6q22 126,007,416 0.93 rs1777198 C T 0.44 4 altered motifs
6q22 126,007,620 0.97 rs2747714 A G 0.44 Ets
6q22 126,007,719 0.94 rs2747715 A T 0.44 5 altered motifs
6q22 126,007,996 0.97 rs78229684 C T 0.44 5 altered motifs
6q22 126,008,435 0.98 rs2747717 A G 0.44
Pou2f2,Pou3f3,So
x
6q22 126,009,109 0.98 rs2747718 C A 0.44 6 altered motifs
6q22 126,009,214 0.98 rs2747719 C T 0.44 Pax-5,TCF4
6q22 126,009,398 0.98 rs2797158 G A 0.44 BATF
AP-1,Hbp1, 
Mrg1::Hoxa9
6q22 126,009,458 0.98 rs2747720 A G 0.44 GM12878 BATF 4 altered motifs
6q22 126,009,527 0.98 rs2747721 A G 0.44 GM12878 BATF 9 altered motifs
6q22 126,009,557 0.97 rs2797159 G A 0.44 GM12878
6q22 126,009,629 0.98 rs2747722 A G 0.44 4 altered motifs
6q22 126,010,086 0.99 rs35069021 AT A 0.44 5 altered motifs
6q22 126,010,116 0.99 rs2797160 A G 0.44 6 altered motifs
6q22 126,010,789 0.92 rs2797161 A G 0.42 GZF1,Smad4
6q22 126,010,790 0.92 rs2747723 C T 0.42 RFX5,Smad4
6q22 126,010,904 0.99 rs34649676 CA C 0.44 CIZ,HNF1,Pou5f1
6q22 126,011,079 0.99 rs1739368 C T 0.44 5 altered motifs
6q22 126,011,231 0.88 rs1739370 C T 0.41 8 altered motifs
6q22 126,011,291 0.99 rs1739371 G A 0.44
6q22 126,011,325 0.99 rs1739372 G A 0.44 4 altered motifs
6q22 126,011,381 0.99 rs2797162 G T 0.44 Pou3f2,p300
6q22 126,011,509 0.99 rs1739373 A G 0.44
CHOP::CEBPalpha,
Pou2f2,Sp4
6q22 126,011,825 0.97 rs1739374 C T 0.44 10 altered motifs
6q22 126,011,995 0.97 rs1777183 A C 0.44 8 altered motifs
6q22 126,012,013 0.97 rs1739375 T C 0.44 7 altered motifs
6q22 126,012,084 0.97 rs1739376 C G 0.44 4 altered motifs
6q22 126,012,236 0.97 rs1739377 T C 0.44
Arid5b,HDAC2,Po
u5f1
6q22 126,012,262 0.99 rs1739378 C A 0.44 Hsf,TEF-1
6q22 126,012,397 0.97 rs2747725 T G 0.44
6q22 126,012,593 0.97 rs1739379 T C 0.44 Pou6f1
6q22 126,012,858 0.97 rs1739380 T C 0.44 5 altered motifs
6q22 126,013,155 0.97 rs1630556 A G 0.44 SETDB1 10 altered motifs
6q22 126,013,614 0.97 rs1777182 T A 0.44 6 altered motifs
6q22 126,014,157 0.99 rs1739347 C T 0.44 Ascl2,Myc,Myf
6q22 126,014,573 0.99 rs1739348 T C 0.44 PU.1
6q22 126,014,907 0.88 rs1612274 C A 0.41 POL2 4 altered motifs
6q22 126,014,916 0.98 rs1612249 C A,T 0.44
6q22 126,014,984 0.99 rs1739349 G C 0.44 Ik-3,Pax-4,Sox
6q22 126,015,057 0.99 rs1578793 A G 0.44 4 altered motifs
6q22 126,015,469 0.99 rs1578794 T C 0.44 4 altered motifs
6q22 126,015,954 0.99 rs6927161 T C 0.44 Foxc1,GATA,Mef2
6q22 126,016,003 0.99 rs6904992 G A 0.44 Myc,Osr
6q22 126,016,499 0.99 rs12717178 G A 0.44 6 altered motifs
6q22 126,016,580 - rs13328298 G A 0.44 14 altered motifs
6q22 126,016,951 0.99 rs6933302 T C 0.44 PRDM1,YY1
6q22 126,017,029 0.99 rs6933471 T G 0.44 DMRT5,HNF1,Irf
6q22 126,017,141 0.98 rs6910786 A T 0.44 9 altered motifs
6q22 126,017,155 0.99 rs6910933 C G 0.44 4 altered motifs
6q22 126,017,481 0.99 rs6934435 T G 0.44 16 altered motifs
6q22 126,017,551 0.99 rs201940333 T TC 0.44 10 altered motifs
6q22 126,017,691 0.99 rs1777226 C A 0.44 H1-hESC BAF155,SP1,WT1
6q22 126,017,808 0.99 rs1739354 G C 0.44
CTCF,ERalpha-
a,RXRA
6q22 126,018,114 0.99 rs1739355 A G 0.44
6q22 126,018,270 0.99 rs1777225 T C 0.44 E2A,LBP-1
6q22 126,019,527 0.96 rs1777224 T C 0.45 BATF,E2F,Irf
6q22 126,019,655 0.96 rs1739357 T G 0.45 EBF,SP1
6q22 126,019,736 0.98 rs1739358 G A 0.44
6q22 126,019,738 0.95 rs200274442 A ACG 0.43 4 altered motifs
6q22 126,019,738 0.98 rs77678056 A G 0.44
6q22 126,019,768 0.98 rs78602343 T C 0.43 Foxp1,Nkx3
6q22 126,020,703 0.98 rs1739362 A T 0.44 Foxj2,Maf
6q22 126,020,980 0.98 rs1739363 G A 0.44 H1
H1-hESC, 
CD20+ EBF1 Pou3f3
6q22 126,021,030 0.98 rs1777222 C T 0.44 H1
H1-hESC, 
CD20+ EBF1 Pax-4
6q22 126,021,277 0.98 rs984040 T C 0.44 Foxp1
6q22 126,021,328 0.98 rs984041 A T 0.44 Pou2f2
6q22 126,021,435 0.98 rs926853 A T 0.44 GATA
6q22 126,021,780 0.96 rs926854 A G 0.43 H1 RPTEC 4 altered motifs
6q22 126,021,782 0.96 rs926855 A G 0.43 H1 RPTEC
HP1-site-
factor,Mef2
6q22 126,022,383 0.91 rs1739364 G A 0.44 H1 4 cell types JUND,POL2,POL24H8
6q22 126,022,602 0.81 rs1777220 G T 0.41 H1
6q22 126,025,819 0.7 rs9491500 A G 0.39 H1 4 altered motifs
6q22 126,027,318 0.71 rs6939865 A C 0.4 H1 11 altered motifs
6q22 126,027,833 0.71 rs144251392 G A 0.4 H1
6q22 126,029,043 0.74 rs1268092 C T 0.41 H1 H1-hESC 5 altered motifs
6q22 126,029,235 0.74 rs1268093 G A 0.41 H1 5 altered motifs
6q22 126,029,682 0.77 rs1269176 T A 0.41 H1 7 altered motifs
6q22 126,031,682 0.77 rs9491503 G A 0.41 En-1
6q22 126,032,104 0.73 rs6569436 A G 0.42 RWPE1
Fox,HP1-site-
factor,Nrf-2
6q22 126,034,540 0.73 rs6569437 T G 0.41 HAc 6 altered motifs
6q22 126,034,563 0.73 rs6939969 C T 0.41 HAc GR,Pax-4,RP58
6q22 126,035,041 0.76 rs1268066 C T 0.41 HBMEC,HNPCEpiC GATA2 Hoxa7
6q22 126,036,184 0.76 rs1343121 C T 0.41 GM12878 4 altered motifs
6q22 126,036,621 0.73 rs1268067 T C 0.41 4 altered motifs
8q24 129,599,278 - rs4733613 C G 0.85 HepG2
8q24 129,497,735 0.71 rs77156523 T A 0.09 Znf143
8q24 129,499,432 0.78 rs77241108 G A 0.09 4 altered motifs
8q24 129,501,028 0.79 rs113834169 CT C 0.09
HSMM, NHLF, 
HepG2 Th1 USF2,USF1 4 altered motifs
8q24 129,501,760 0.79 rs76384007 C T 0.09 HepG2 MAFK Hand1,RXRA,VDR
8q24 129,502,569 0.79 rs10505515 A G 0.09 HepG2 HRPEpiC Foxa,Mef2
8q24 129,503,700 0.79 rs17805799 T C 0.09 10 altered motifs
8q24 129,506,822 0.79 rs77683961 G A 0.09 HepG2
8q24 129,507,019 0.79 rs75706585 C T 0.09 Nr2e3
8q24 129,508,906 0.79 rs17231703 G C 0.09
8q24 129,514,190 0.79 rs17805924 A C 0.09 HepG2 SP1
8q24 129,517,137 0.79 rs17231857 T C 0.09 4 altered motifs
8q24 129,517,554 0.79 rs17231948 A G 0.09 Ets
8q24 129,517,938 0.79 rs76388889 T C 0.09 Cdx,DMRT1
8q24 129,526,064 0.81 rs17232172 C T 0.09 HepG2, H1, NHEK E2F,Smad3
8q24 129,529,129 0.81 rs1878378 T A 0.09 HNF4
8q24 129,530,492 0.81 rs1400485 A G 0.09 Hoxb13
8q24 129,537,624 0.88 rs79593486 A C 0.1 NHLF 10 altered motifs
8q24 129,537,746 - rs17232730 G C 0.09 NHLF 8 cell types
8q24 129,545,257 0.76 rs1516973 C T 0.08 HepG2, HSMM
8q24 129,546,233 0.76 rs1607120 G A 0.08 NHLF 7 cell types 6 altered motifs
8q24 129,546,982 0.76 rs10086718 T C 0.08 11 altered motifs
8q24 129,548,654 0.76 rs74866331 T C 0.08 TLX1::NFIC
8q24 129,549,261 0.76 rs1516977 A G 0.08 ERALPHA_A 7 altered motifs
8q24 129,550,041 0.76 rs10112057 G A 0.08 Th1,Th2 4 altered motifs
8q24 129,551,752 0.76 rs10088873 G A 0.08 HSMM, HepG2 Pbx-1
8q24 129,552,140 0.76 rs10098999 C T 0.08 4 cell types 4 cell types HNF4A,HNF4G,RXRA 4 altered motifs
8q24 129,555,724 0.72 rs2138636 C T 0.08 NHLF, HSMM 9 cell types 5 altered motifs
8q24 129,555,928 0.73 rs17807904 G A 0.08 HSMM
Th1,Adult_
CD4_Th0
Myc,RBP-
Jkappa,Zfx
8q24 129,556,514 0.73 rs10087367 G A 0.08 7 altered motifs
8q24 129,559,228 0.73 rs10098821 C T 0.08 7 altered motifs
8q24 129,560,314 0.72 rs10102835 C T 0.08 17 altered motifs
8q24 129,562,824 0.73 rs76076434 G A 0.08 5 altered motifs
8q24 129,563,362 0.72 rs78830272 T C 0.08 5 altered motifs
8q24 129,565,545 0.73 rs75370373 G T 0.08 HepG2, K562
K562, 
Jurkat, Th2 E2F6,MAX
Egr-
1,SETDB1,Znf143
8q24 129,566,898 0.73 rs7007074 C T 0.08
HepG2, K562, 
NHLF 11 altered motifs
15q15 40,290,475 0.71 rs199884855 TG T 0.58 19 altered motifs
15q15 40,302,243 0.72 rs3816900 C T 0.55 HSMM
FXR,HNF1,RORalp
ha1
15q15 40,302,441 0.72 rs12592831 G A 0.55 HSMM BE2_C Myf
15q15 40,303,842 0.72 rs2412464 G A 0.55 HSMM Sin3Ak-20
15q15 40,322,124 - rs937213 T C 0.44 FibroP 7 altered motifs
14q32 105,192,685 0.74 rs72715972 G A 0.32 HepG2
HMEC, 
Fibrobl, HL-
60 5 altered motifs
14q32 105,196,230 0.79 rs80097179 A C 0.31 K562 4 bound proteins Znf143
14q32 105,197,354 0.78 rs60876857 C G 0.32 K562 Roaz
14q32 105,197,756 0.79 rs60798007 G C 0.31 HepG2
40 cell 
types 9 bound proteins 9 altered motifs
14q32 105,197,846 0.77 rs57098433 G A 0.32 HepG2
30 cell 
types 8 bound proteins NF-E2,PLZF
14q32 105,203,678 0.79 rs7160733 G A 0.32 Huvec, HepG2 SP1,ZEB1
14q32 105,208,057 0.8 rs4983384 C T 0.32 5 altered motifs
14q32 105,218,333 0.76 rs8006580 G A 0.33
HepG2, 
GM12878, HMEC GM06990 SETDB1 Hic1
14q32 105,222,037 0.79 rs1132975 C T 0.33 HepG2 GM12878 RXRA
14q32 105,226,075 0.79 rs45607139 C T 0.33 17 altered motifs
14q32 105,228,216 0.8 rs4983549 G A 0.33 7 altered motifs
14q32 105,229,646 0.85 rs7158655 T C 0.32 HepG2 13 altered motifs
14q32 105,230,225 0.84 rs144188214 TTTTA T 0.32 HepG2 34 altered motifs
14q32 105,230,391 0.74 rs28368454 T C 0.33 HepG2 HMG-IY,NRSF
14q32 105,231,196 0.79 rs66464514 A G 0.33 HepG2 RP58,Sox,TAL1
14q32 105,231,640 0.77 rs4983550 T G 0.35 HepG2 Hltf,Sox
14q32 105,233,095 0.85 rs2498804 C A 0.32 HepG2 H1, K562 HepG2 POL2 Nkx2,Nkx3
14q32 105,233,408 0.85 rs2498803 G A 0.32 HepG2, K562 H7-hESC 7 bound proteins
CCNT2, NF-
kappaB, 
UF1H3BETA
14q32 105,233,421 0.85 rs2494730 T A 0.32 HepG2, K562 H7-hESC 7 bound proteins 6 altered motifs
14q32 105,234,442 0.78 rs2498802 G C 0.34 HepG2 Fibrobl 5 altered motifs
14q32 105,235,558 0.79 rs2498801 T C 0.34 HepG2 K562, H1 6 cell types CTCF,AP2ALPHA,POL2 5 altered motifs
14q32 105,237,680 0.82 rs2494731 G C 0.34 SETDB1 Pax-5,RXRA
14q32 105,238,591 0.87 rs55839843 CCTGAG C 0.32 PrEC 4 altered motifs
14q32 105,240,784 0.89 rs2494733 C G 0.33 ERALPHA_A,CTCF 8 altered motifs
14q32 105,242,228 0.85 rs2498797 T C 0.34 4 cell types ERALPHA_A,POL2,CMYC 6 altered motifs
14q32 105,242,831 0.98 rs3001371 C T 0.31 ZNF263 RREB-1
14q32 105,242,966 0.77 rs2494735 T C 0.37 ZNF263 5 altered motifs
14q32 105,243,220 - rs2498796 G A 0.31 4 altered motifs
LD, r2 with lead SNP; Ref,reference allele; alt, alternative allele; EUR AF, reference allele frequency in Europeans; DHS, DNase1 hypersensitivity site; TFBS, Transcription Factor Binding Sites
GWAS hits are noted in bold
RegulomeDB scores:
1b: eQTL + TF binding + any motif + DNase Footprint + DNase peak
1c: eQTL + TF binding + matched TF motif + DNase peak
1d: eQTL + TF binding + any motif + DNase peak
1e: eQTL + TF binding + matched TF motif
1f: eQTL + TF binding / DNase peak
2a: TF binding + matched TF motif + matched DNase Footprint + DNase peak
2b: TF binding + any motif + DNase Footprint + DNase peak
2c: TF binding + matched TF motif + DNase peak
3a: TF binding + any motif + DNase peak
3b: TF binding + matched TF motif
4: TF binding + DNase peak 
5: TF binding or DNase peak 
6: other
Phastcons derived from hg19_phastConsElements46way.txt using annovar
10kb 3' of RNY1P8 5
11kb 3' of RNY1P8
12kb 3' of RNY1P8
12kb 3' of RNY1P8
13kb 3' of RNY1P8
13kb 3' of RNY1P8
RP11-624M8.1
RP11-624M8.1 5
RP11-624M8.1 6
RP11-624M8.1 5 Score=451;Name=lod=91
RP11-624M8.1 5
RP11-624M8.1 6
RP11-624M8.1
RP11-624M8.1 5
RP11-624M8.1
RP11-624M8.1
RP11-624M8.1 5
RP11-624M8.1 5
RP1-293L8.2 5
RP1-293L8.2 5
RP1-293L8.2 5
RP1-293L8.2 intronic 5
RP1-293L8.2 intronic 3a
RP1-293L8.2 intronic 5
RP1-293L8.2 intronic 5
RP1-293L8.2 intronic 5
dbSNP 
annotation
Regulome
DB score
PhastConsGENCODE genes
RP1-293L8.2 intronic
RP1-293L8.2 intronic
RP1-293L8.2 intronic 5
RP1-293L8.2 intronic 5
RP1-293L8.2 intronic 4
RP1-293L8.2 intronic 3a
RP1-293L8.2 intronic 3a
RP1-293L8.2 intronic 5
RP1-293L8.2 intronic
RP1-293L8.2 intronic 5 Score=497;Name=lod=139
RP1-293L8.2 intronic
RP1-293L8.2 intronic
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic
RP1-293L8.2 intronic
RP1-293L8.2 intronic Score=272;Name=lod=17
RP1-293L8.2 intronic
RP1-293L8.2 intronic
RP1-293L8.2 intronic 3a
RP1-293L8.2 intronic
RP1-293L8.2 intronic 3a
RP1-293L8.2 intronic 5
RP1-293L8.2 intronic
RP1-293L8.2 intronic
RP1-293L8.2 intronic
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic
RP1-293L8.2 intronic 5
RP1-293L8.2 intronic 3a
RP1-293L8.2 intronic 4
RP1-293L8.2 intronic 3a
RP1-293L8.2 intronic
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic
RP1-293L8.2 intronic
RP1-293L8.2 intronic
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic
RP1-293L8.2 intronic
RP1-293L8.2 intronic
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic 5
RP1-293L8.2 intronic 5
RP1-293L8.2 intronic 5
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic
RP1-293L8.2 intronic
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic
RP1-293L8.2 intronic 5
RP1-293L8.2 intronic 5
RP1-293L8.2 intronic
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic
RP1-293L8.2 intronic 3a
RP1-293L8.2 intronic 4
RP1-293L8.2 intronic 5
RP1-293L8.2 intronic 5
RP1-293L8.2 intronic 5
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic
RP1-293L8.2 intronic
RP1-293L8.2 intronic
RP1-293L8.2 intronic
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic 5
RP1-293L8.2 intronic
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic
RP1-293L8.2 intronic
RP1-293L8.2 intronic
RP1-293L8.2 intronic
RP1-293L8.2 intronic
RP1-293L8.2 intronic 4
RP1-293L8.2 intronic 4
RP1-293L8.2 intronic
RP1-293L8.2 intronic
RP1-293L8.2 intronic
RP1-293L8.2 intronic 5 Score=321;Name=lod=27
RP1-293L8.2 intronic 5 Score=321;Name=lod=27
RP1-293L8.2 intronic 4 Score=346;Name=lod=34
RP1-293L8.2 intronic 5
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic
RP1-293L8.2 intronic 5 Score=608;Name=lod=393
RP1-293L8.2 intronic Score=343;Name=lod=33
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic 3a
RP1-293L8.2 intronic 5
RP1-293L8.2 intronic 5
RP1-293L8.2 intronic 4
RP1-293L8.2 intronic 6
RP1-293L8.2 intronic 3a
22kb 5' of RP11-89M16.1
RP11-89M16.1
RP11-89M16.1 6
RP11-89M16.1 3a
RP11-89M16.1 3a
RP11-89M16.1 5
RP11-89M16.1 6
RP11-89M16.1 5
RP11-89M16.1 5
RP11-89M16.1
RP11-89M16.1 5
RP11-89M16.1 5
RP11-89M16.1
RP11-89M16.1
RP11-89M16.1
RP11-89M16.1
RP11-89M16.1
RP11-89M16.1 3b
RP11-89M16.1 4
RP11-89M16.1
RP11-89M16.1 5
RP11-89M16.1 6
RP11-89M16.1 5
RP11-89M16.1 2b Score=669;Name=lod=696
RP11-89M16.1 5
RP11-89M16.1
RP11-89M16.1 4
RP11-89M16.1 4
RP11-89M16.1 5
RP11-89M16.1
RP11-89M16.1
RP11-89M16.1 6
RP11-89M16.1 6
RP11-89M16.1 6
RP11-89M16.1 3a
RP11-89M16.1 5 Score=309;Name=lod=24
EIF2AK4 intronic
EIF2AK4 intronic
EIF2AK4 intronic 5
EIF2AK4 intronic
EIF2AK4 intronic 5
ADSSL1 intronic 2b
ADSSL1 missense 4
ADSSL1 intronic 5
ADSSL1 intronic 4
ADSSL1 intronic 4 Score=317;Name=lod=26
ADSSL1 intronic
ADSSL1 intronic 1f
1.1kb 5' of SIVA1 4 Score=498;Name=lod=141
SIVA1 synonymous 6
SIVA1 2b
SIVA1 6
SIVA1 5
SIVA1 6
SIVA1 6
SIVA1 6
SIVA1
SIVA1 1b
SIVA1 4
SIVA1 1b
SIVA1 1f
127bp 5' of RP11-982M15.2 4
AKT1 intronic 1f
AKT1 intronic
AKT1 intronic 2b
AKT1 intronic 2b
AKT1 intronic 1b
AKT1 intronic 4
AKT1 intronic 5
LD, r2 with lead SNP; Ref,reference allele; alt, alternative allele; EUR AF, reference allele frequency in Europeans; DHS, DNase1 hypersensitivity site; TFBS, Transcription Factor Binding Sites
Supplementary Table 7: Pairwise t-test P-values for 13q22 luciferase assays
rs11841589-T rs11841589-G rs9600103-T rs9600103-A pGL3
rs11841589-T - 0.058 0.128 0.045 0.008
rs11841589-G - - 0.979 0.039 0.013
rs9600103-T - - - 0.018 0.014
rs9600103-A - - - - 0.226
pGL3 - - - - -
P-values from paired t-test comparisons using average of biological replicates. 
Results unadjusted for multiple comparisons.
Supplementary Table 8: Primers and oligos used in experimental procedures
Locus Primer name Forward sequence Reverse sequence
13q22 13q22_n2_rs10047671 TGCCATGGTTATTCTGAGCTTC ACCATCTTCATTTTGTGTGGCT
13q22 13q22_n1_rs9564955 ATGCAATGCCACAATCTCGG CTGGGCAATGTAAAGGGACC
13q22 13q22_0_rs56207966 TGCCACCCACCATACTTACT AACCCAGGAGTCAGAGGTTG
13q22 13q22_1_rs78441730 AGCCCATCTCCTCCATGAAG ACTGGAAGTGAAGGTGGAGT
13q22 13q22_2_rs6562748 GGCCAGGCTTGATCTCCTAA CTCTCTTGGACCTGGCCAC
13q22 13q22_3_rs7996454 TCTTGGGCTCGAACAATCCT GTGACAGAGTGAGAGCCTGT
13q22 13q22_4_rs9600103 CTGTGGTAGAGATTGATGATGGT ACTCACTCCGGGAAAGAAGA
13q22 13q22_5_rs12429143 AATGGTTTGGTTCAGGGTTCT CATGATCGTGCCACTCCAG
13q22 13q22_6_rs9592895 TGTCTGATGGCTGAAAGAAATCC GGTGGGAAAGGTGCAAATGA
13q22 13q22_7_rs11841589 GTTGGCCAGTGTGTGCTC GAGACAGCGTTTCACCATGT
13q22 13q22_8_rs7995365 CCCTGCAGGCTATAGTTATTGAG TGCCTATCTTCAGTAATGACCAA
13q22 13q22_9_rs8001970 AGGCCACAGACATCATGGAA TTCCAGAAGAATCCCTGGGG
13q22 13q22_10_rs9543288 GTGAAGGTTACAGTGAGCCG TGTGGAAATTTTAGGCCTCTGA
13q22 13q22_11_rs7328804 CATCACTGTGGCAAGGGAAC GGCCTATGAAGTGTGAAGCG
13q22 13q22_12_rs186045575 GGGCCTTGCACTAAAAGATGT ACAATCCGCGCTATAATGCC
12p13 GAPDH GAGCCTCGAGGAGAAGTTCC ACGACTGAGATGGGGAATTG 
3q22 RHO TAACTTGTGGGGGAACGAAC ATGGGCCTCTGTGCTATGTC 
13q22 Luc_rs9600103 GGCTGAGCTCAAACTCTTGG GGGGCATAAAATTAACTTGACA
13q22 Luc_rs11841589 GGAGACAGGTATGTTGAAAGCTC ACAGATTTGTGCCACCACAC
13q22 SDM_rs9600103_A GAAAAATCATTTCCCAGTTCTCTATCCATTCATATTGTTGTGG CCACAACAATATGAATGGATAGAGAACTGGGAAATGATTTTTC
13q22 SDM_rs9600103_T GAAAAATCATTTCCCTGTTCTCTATCCATTCATATTGTTGTGG CCACAACAATATGAATGGATAGAGAACAGGGAAATGATTTTTC
13q22 SDM_rs11841589_G CATTTTATATACATCTTAACAGATTCTAGTCAGGCACAGTGGC GCCACTGTGCCTGACTAGAATCTGTTAAGATGTATATAAAATG
13q22 SDM_rs11841589_T CATTTTATATACATCTTAACATATTCTAGTCAGGCACAGTGGC GCCACTGTGCCTGACTAGAATATGTTAAGATGTATATAAAATG
8q25 KASP_rs4733613 GAAGGTGACCAAGTTCATGCTGTGAGTCAATTAAACCTTTTTCTCAGC TTGTATTAGTCTGCTCTCACACTGCTAAT
GAAGGTCGGAGTCAACGGATTGTGAGTCAATTAAACCTTTTTCTCAGG TCTGCTCTCACACTGCTAATAAAGACATA
15q15 KASP_937213 GAAGGTGACCAAGTTCATGCTGCCAAATATGTCTTCTCATGGCCTTA GCCTTTGCTTTCATCACCTCTAGCAA
GAAGGTCGGAGTCAACGGATTCCAAATATGTCTTCTCATGGCCTTG TTCATCACCTCTAGCAACCTTACTTCTTT
14q32 KASP_rs2498796 GAAGGTGACCAAGTTCATGCTCATACCACCCACCAGGTCCTG GGAGAGAGGAAGAGATGGGGCTT
GAAGGTCGGAGTCAACGGATTCATACCACCCACCAGGTCCTA AGAAACTGAGGCTTGGAGAGAGGAA
Specific Target Amplification / Locus Specific Primer Allele Specific Primer 1&2
13q22 rs11841589 CAAAGTGCTGGGATTACAGGT GCCACTGTGCCTGACTAGAATC
TGGCCAGTGTGTGCTCAAGA GCCACTGTGCCTGACTAGAATA
6q22 rs13328298 ACAAATGGCCAAGAGATACATGAAA GAAAGGTGGTCAACATCGCTAATT
ACCTGCCTTTTTAGCAGGTATAAGGT GAAAGGTGGTCAACATCGCTAATC
15q15 rs937213 GTGCTAACAGAAGAGAATGGGAAA GCCAAATATGTCTTCTCATGGCCTTA
TGCTTTCATCACCTCTAGCAACCT CCAAATATGTCTTCTCATGGCCTTG
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